

# CITATION REPORT

List of articles citing

Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review

DOI: 10.1016/s2214-109x(17)30375-3  
The Lancet Global Health, 2017, 5, e1192-e1207.

**Source:** <https://exaly.com/paper-pdf/66786508/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
859	Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. <i>The Lancet Global Health</i> , <b>2017</b> , 5, e1208-e1220	13.6	236
858	Estimates are not enough: scaling-up interventions to improve the health of people who inject drugs. <i>The Lancet Global Health</i> , <b>2017</b> , 5, e1162-e1163	13.6	1
857	Estimating the number of people who inject drugs in Australia. <b>2017</b> , 17, 757		25
856	Injecting drug use: Gendered risk. <b>2018</b> , 56, 81-91		8
855	Hepatitis C virus status awareness and test results confirmation among people who inject drugs in Ukraine. <b>2018</b> , 57, 11-17		10
854	EASL Recommendations on Treatment of Hepatitis C 2018. <b>2018</b> , 69, 461-511		1079
853	Research gaps in viral hepatitis. <b>2018</b> , 21 Suppl 2, e25054		5
852	Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era. <b>2018</b> , 52, 115-122		11
851	The next wave of hepatitis C virus: The epidemic of intravenous drug use. <b>2018</b> , 38 Suppl 1, 34-39		20
850	Improvements in Quality of Life: A New Indication for Treating Hepatitis C Virus Infection in Persons With Substance Use Disorders. <b>2018</b> , 217, 1020-1023		5
849	Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. <b>2018</b> , 3, 153-161		155
848	Time to end treatment restrictions for people with hepatitis C who inject drugs. <b>2018</b> , 3, 142-143		1
847	Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. <b>2018</b> , 5, ofy001		27
846	Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India. <b>2018</b> , 57, 51-60		7
845	Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets. <b>2018</b> , 55, 31-39		52
844	High HIV seroconversion rate in hepatitis C virus-infected drug users followed in a harm reduction unit: a lost opportunity for preexposure prophylaxis. <b>2018</b> , 32, 1157-1163		2
843	Extending a Helping Hand: Addressing Hepatitis C in Economic Migrants and Refugees. <b>2018</b> , 17, 8-10		3

842	Diagnosis and treatment of hepatitis C virus infection: a tool for engagement with people who inject drugs in Vancouver's Downtown Eastside. <b>2018</b> , 1, 14-33	6
841	HIV, HBV and HCV in people who inject drugs and are placed on methadone maintenance therapy, Yangon, Myanmar. <b>2018</b> , 8, 202-210	5
840	Public health interventions for reducing HIV, hepatitis B and hepatitis C infections in people who inject drugs. <b>2018</b> , 8, 153	1
839	Hepatitis C virus screening and treatment in Irish prisons from a governor and prison officer perspective - a qualitative exploration. <b>2018</b> , 6, 23	12
838	Emergence of New Epidemiological Hepatitis B and C Profiles in High Risk Groups in Latin America. <b>2018</b> ,	1
837	Substance use and universal access to HIV testing and treatment in sub-Saharan Africa: implications and research priorities. <b>2018</b> , 4, 26-32	15
836	High proportions of liver fibrosis and cirrhosis in an ageing population of people who use drugs in Amsterdam, The Netherlands. <b>2018</b> , 30, 1168-1176	4
835	Epidemiology of HIV, syphilis, and hepatitis B and C among manual cane cutters in low-income regions of Brazil. <b>2018</b> , 18, 546	5
834	The number of FoxP3 regulatory T cells in the circulation may be a predictive biomarker for kidney transplant recipients: A multistage systematic review. <b>2018</b> , 65, 483-492	7
833	Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. <b>2018</b> , 3, 754-767	117
832	HCV treatment for people with recent drug use: time for new measures of success?. <b>2018</b> , 3, 731-732	
831	Differences by sex in associations between injection drug risks and drug crime conviction among people who inject drugs in Almaty, Kazakhstan. <b>2018</b> , 60, 96-106	3
830	HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination. <b>2018</b> , 13, e0204795	5
829	Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study. <b>2018</b> , 62, 104-111	6
828	Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia. <b>2018</b> , 61, 23-30	27
827	Peer-to-peer injection: Demographic, drug use, and injection-related risk factors. <b>2018</b> , 61, 44-51	8
826	Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. <b>2018</b> , 62, 94-103	14
825	Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. <b>2018</b> , 18, 1397-1409	86

824	Pathways to ensure universal and affordable access to hepatitis C treatment. <b>2018</b> , 16, 175	41
823	Current Opioid Access, Use, and Problems in Central and Western European Jurisdictions. <b>2018</b> , 5, 478-484	1
822	Hepatitis C virus prevention and care for drug injectors: the French approach. <b>2018</b> , 3, 7	11
821	Management of acute HCV infection in the era of direct-acting antiviral therapy. <b>2018</b> , 15, 412-424	45
820	Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs. <b>2018</b> , 32, 371-393	18
819	Female Gender and HIV Transmission Risk Behaviors Among People Living with HIV Who Have Ever Used Injection Drugs in St. Petersburg, Russia. <b>2018</b> , 22, 2830-2839	2
818	Getting to Zero: We Can't Do It Without Addressing Substance Use. <b>2018</b> , 30, 225-231	3
817	Frequency and factors associated with providing injection initiation assistance in Tallinn, Estonia. <b>2018</b> , 188, 64-70	12
816	Measuring individual-level needle and syringe coverage among people who inject drugs in Myanmar. <b>2018</b> , 58, 22-30	4
815	Intelligent Network Disruption Analysis (INDRA): A targeted strategy for efficient interruption of hepatitis C transmissions. <b>2018</b> , 63, 204-215	5
814	Young Drug Users: a Vulnerable Population and an Underutilized Resource in HIV/HCV Prevention. <b>2018</b> , 15, 324-335	14
813	Direct-acting antiviral treatment of acute hepatitis C virus infections. <b>2018</b> , 16, 599-610	3
812	Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study. <b>2018</b> , 5, e578-e587	20
811	Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada. <b>2018</b> , 59, 76-84	16
810	Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission. <b>2018</b> , 392, 312-358	135
809	Strategies to control HIV and HCV in methadone maintenance treatment in Guangdong Province, China: a system dynamic modeling study. <b>2018</b> , 13, 1	20
808	Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. <b>2018</b> , 113, 1905-1926	371
807	Competing global statistics on prevalence of injecting drug use: why does it matter and what can be done?. <b>2018</b> , 113, 1768-1774	7

806	Prevalence of hepatitis C virus in young people who inject drugs in four Colombian cities: A cross-sectional study using Respondent Driven Sampling. <b>2018</b> , 60, 56-64	5
805	Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison. <b>2018</b> , 25, 1526-1532	33
804	The global health and equity imperative for safe consumption facilities. <b>2018</b> , 392, 553-554	10
803	Factors associated with methadone maintenance therapy discontinuation among people who inject drugs. <b>2018</b> , 94, 41-46	27
802	When Enough Is Not Enough: Screening, Brief Intervention and Referral to Treatment for Hepatitis C in Patients Presenting to the Emergency Department. <b>2018</b> , 25, 1299-1301	
801	Real-world Efficacy of Direct-Acting Antiviral Therapy for HCV Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary Setting. <b>2018</b> , 5, ofy120	28
800	Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. <b>2019</b> , 114, 150-166	110
799	Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study. <b>2019</b> , 26, 1388-1403	9
798	Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes. <b>2019</b> , 104, 34-41	3
797	Hepatitis C elimination: a Public Health Perspective. <b>2019</b> , 17, 367-377	11
796	The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis. <b>2019</b> , 73, 172-184	38
795	Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. <b>2019</b> , 72, 1-10	24
794	Macro-efforts for the micro-elimination of hepatitis C targeting people who inject drugs. <b>2019</b> , 85, 141-142	3
793	High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units. <b>2019</b> , 72, 181-188	12
792	Zinc deficiency and advanced liver fibrosis among HIV and hepatitis C co-infected anti-retroviral naïve persons with alcohol use in Russia. <b>2019</b> , 14, e0218852	11
791	Global progress on the elimination of viral hepatitis as a major public health threat: An analysis of WHO Member State responses 2017. <b>2019</b> , 1, 81-89	42
790	Narratives of people who inject drugs on factors contributing to opioid overdose. <b>2019</b> , 74, 26-32	3
789	HIV drug resistance in persons who inject drugs enrolled in an HIV prevention trial in Indonesia, Ukraine, and Vietnam: HPTN 074. <b>2019</b> , 14, e0223829	8

788	Regulatory Policies for Alcohol, other Psychoactive Substances and Addictive Behaviours: The Role of Level of Use and Potency. A Systematic Review. <b>2019</b> , 16,	15
787	Global patterns of opioid use and dependence: harms to populations, interventions, and future action. <b>2019</b> , 394, 1560-1579	182
786	Responding to global stimulant use: challenges and opportunities. <b>2019</b> , 394, 1652-1667	83
785	Long term surgical outcomes for infective endocarditis in people who inject drugs: a systematic review and meta-analysis. <b>2019</b> , 19, 918	19
784	Adverse health effects of abuse-deterrent opioids: Evidence from the reformulation of OxyContin. <b>2019</b> , 28, 1449-1461	10
783	We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. <b>2019</b> , 286, 503-525	39
782	Hepatitis C. <b>2019</b> , 394, 1451-1466	155
781	I could take the judgment if you could just provide the service: non-prescription syringe purchase experience at Arizona pharmacies, 2018. <b>2019</b> , 16, 57	11
780	Barriers to effective management of hepatitis C virus in people who inject drugs: Evidence from outpatient clinics. <b>2019</b> , 38, 644-655	11
779	Countdown to 2030: eliminating hepatitis B disease, China. <b>2019</b> , 97, 230-238	102
778	Cure and Control: What Will It Take to Eliminate HCV?. <b>2019</b> , 447-490	1
777	Innovative strategies for the elimination of viral hepatitis at a national level: A country case series. <b>2019</b> , 39, 1818-1836	25
776	Hepatitis C virus infection in Irish drug users and prisoners - a scoping review. <b>2019</b> , 19, 702	4
775	HIV- and hepatitis C-related risk behaviors among people who inject drugs in Uganda: implications for policy and programming. <b>2019</b> , 16, 56	3
774	Syringe Quantity Limitations: Syringe Exchange Program Participant Health Behavior and Satisfaction. <b>2019</b> , 19, 400-413	1
773	Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study. <b>2019</b> , 19, 1255-1263	17
772	The case for a universal hepatitis C vaccine to achieve hepatitis C elimination. <b>2019</b> , 17, 175	9
771	Cost-Effectiveness of One-Time Birth Cohort Screening for Hepatitis C as Part of the National Health Service Health Check Program in England. <b>2019</b> , 22, 1248-1256	5

770	Access to hepatitis C care for people who inject drugs and people in prisons. <b>2019</b> , 4, 662-663	2
769	Seizures of illicit substances for personal use in two Italian provinces: analysis of trends by type and purity from 2008 to 2017. <b>2019</b> , 14, 41	3
768	Social Networks of Substance-Using Populations: Key Issues and Promising New Approaches for HIV. <b>2019</b> , 16, 48-56	5
767	Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. <b>2019</b> , 393, 1319-1329	130
766	Transgenic increase in the $\mu$ -endorphin concentration in cerebrospinal fluid alleviates morphine-primed relapse behavior through the $\mu$ -opioid receptor in rats. <b>2019</b> , 91, 1158-1167	4
765	Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States. <b>2019</b> , 69, 1888-1895	40
764	Interpersonal and structural factors associated with receptive syringe-sharing among a prospective cohort of female sex workers who inject drugs. <b>2019</b> , 114, 1204-1213	20
763	Factors associated with health-related quality of life in a large national sample of patients receiving opioid substitution treatment in Germany: A cross-sectional study. <b>2019</b> , 14, 2	16
762	Hepatitis C virus screening and treatment in Irish prisons from nurse managers' perspectives - a qualitative exploration. <b>2019</b> , 18, 23	2
761	Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada. <b>2019</b> , 72, 106-113	10
760	Estimating the size of key populations for HIV in Singapore using the network scale-up method. <b>2019</b> , 95, 602-607	14
759	Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project. <b>2019</b> , 72, 61-68	10
758	Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis. <b>2019</b> , 70, 87-93	5
757	Epidemiology of blood-borne viral infections in Afghanistan. <b>2019</b> , 164, 2083-2090	2
756	Challenges to Studying Illicit Drug Users. <b>2019</b> , 51, 480-488	7
755	HIV, Drug Injection, and Harm Reduction Trends in Eastern Europe and Central Asia: Implications for International and Domestic Policy. <b>2019</b> , 21, 47	10
754	Prevalence and correlates of HIV infection among people who use drugs in Cambodia: a cross-sectional survey using respondent driven sampling method. <b>2019</b> , 19, 515	6
753	Social inclusion from on high: A poststructural comparative content analysis of drug policy texts from Canada and Scotland. <b>2019</b> , 71, 19-28	1

752	Young people who inject drugs in India have high HIV incidence and behavioural risk: a cross-sectional study. <b>2019</b> , 22, e25287	5
751	Evaluation of contingency management as a strategy to improve HCV linkage to care and treatment in persons attending needle and syringe programs: A pilot study. <b>2019</b> , 69, 1-7	13
750	Identification of a New HCV Subtype 6xg Among Injection Drug Users in Kachin, Myanmar. <b>2019</b> , 10, 814	5
749	Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan. <b>2019</b> , 2, e193613	24
748	Integrated care for methadone maintenance patients with hepatitis C virus infection. <b>2019</b> , 35, 501-507	2
747	Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey. <b>2019</b> , 16, 29	5
746	Hepatitis C screening in hospitals: find the missing patients. <b>2019</b> , 16, 47	8
745	Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy. <b>2019</b> , 3, 478-492	16
744	Family and social predictors of substance use disorder in Iran: a case-control study. <b>2019</b> , 14, 17	10
743	Injection of cocaine is associated with a recent HIV outbreak in people who inject drugs in Luxembourg. <b>2019</b> , 14, e0215570	10
742	Participation pattern of methadone users and its association with social connection and HIV status: Analyses of electronic health records data. <b>2019</b> , 14, e0216727	1
741	Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs. <b>2019</b> , 72, 11-23	14
740	Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infections among people who inject drugs in Kuwait: A cross-sectional study. <b>2019</b> , 9, 6292	4
739	Trends in substance use and in the attributable burden of disease and mortality in the WHO European Region, 2010-16. <b>2019</b> , 29, 723-728	21
738	On the way to Hepatitis C elimination in the Republic of Georgia-Barriers and facilitators for people who inject drugs for engaging in the treatment program: A formative qualitative study. <b>2019</b> , 14, e0216123	13
737	Trends in occurrence and 30-day mortality of infective endocarditis in adults: population-based registry study in Finland. <b>2019</b> , 9, e026811	23
736	Navigating social norms of injection initiation assistance during an overdose crisis: A qualitative study of the perspectives of people who inject drugs (PWID) in Vancouver, Canada. <b>2019</b> , 69, 24-33	8
735	The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. <b>2019</b> , 4, 435-444	74



734	Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance. <b>2019</b> , 27, 86-95	9
733	Syndemic and Synergistic Effects of Intimate Partner Violence, Crystal Methamphetamine, and Depression on HIV Sexual Risk Behaviors among Women Who Inject Drugs in Indonesia. <b>2019</b> , 96, 477-496	10
732	Age of Initiation and Patterns of Use among People Who Inject Drugs Welcomed in Harm Reduction Facilities in France from 2006 to 2015. <b>2019</b> , 51, 260-271	
731	Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review. <b>2019</b> , 33, e22876	13
730	Estimating HIV and HCV prevalence among people who inject drugs in 5 Ukrainian cities using stratification-based respondent driven and random sampling. <b>2019</b> , 67, 91-101	4
729	History of detention and the risk of hepatitis C among people who inject drugs in Germany. <b>2019</b> , 81, 100-106	5
728	The necessity of education and hepatitis B vaccination for young people: A study of high risk behaviour for blood borne viruses in the United Kingdom. <b>2019</b> , 23, 437-445	2
727	Screening for hepatitis C in a general adult population in a low-prevalence area: the Tromsø study. <b>2019</b> , 19, 189	3
726	Hepatitis C services at harm reduction centres in the European Union: a 28-country survey. <b>2019</b> , 16, 20	3
725	Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs. <b>2019</b> , 16, 14	8
724	A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015. <b>2019</b> , 22, e25222	3
723	Who to Test for Hepatitis C Virus in the Middle East and North Africa?: Pooled Analyses of 2,500 Prevalence Measures, Including 49 Million Tests. <b>2019</b> , 3, 325-339	15
722	Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry. <b>2019</b> , 49, 1052-1059	41
721	Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey. <b>2019</b> , 16, 28	22
720	Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis. <b>2019</b> , 6, e315-e324	32
719	Attitudes towards people living with HIV and people who inject drugs: A mixed method study of stigmas within harm reduction programs in Kazakhstan. <b>2019</b> , 68, 27-36	6
718	Integrated HIV prevention and care for key populations. <b>2019</b> , 6, e270-e271	2
717	A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs-Do Gender-Based Differences Vary by Country-Level Indicators?. <b>2019</b> , 220, 78-90	17

716	HIV risk behaviours among women who inject drugs in coastal Kenya: findings from secondary analysis of qualitative data. <b>2019</b> , 16, 10	9
715	Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. <b>2019</b> , 66, 73-79	20
714	Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs. <b>2019</b> , 66, 87-93	10
713	New Face of Hepatitis C. <b>2019</b> , 64, 1782-1788	15
712	Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial. <b>2019</b> , 170, 594-603	69
711	Do combination HIV prevention programmes result in increased empowerment, inclusion and agency to demand equal rights for marginalised populations in low-income and middle-income countries? A systematic review. <b>2019</b> , 4, e001560	3
710	Improved Health Outcomes from Hepatitis C Treatment Scale-Up in Spain's Prisons: A Cost-Effectiveness Study. <b>2019</b> , 9, 16849	10
709	Opioid agonist treatment scale-up and the initiation of injection drug use: A dynamic modeling analysis. <b>2019</b> , 16, e1002973	14
708	Occurrence of fatal infective endocarditis: a population-based study in Finland. <b>2019</b> , 19, 987	7
707	Diversity of hepatitis C virus infection among HIV-infected people who inject drugs in India. <b>2019</b> , 30, 490-497	2
706	Association of Self-Reported Abscess With High-Risk Injection-Related Behaviors Among Young Persons Who Inject Drugs. <b>2019</b> , 30, 142-150	6
705	Parameter estimates for trends and patterns of excess mortality among persons on antiretroviral therapy in high-income European settings. <b>2019</b> , 33 Suppl 3, S271-S281	1
704	Perceived need, barriers to and facilitators of mental health care among HIV-infected PWID in Hanoi, Vietnam: a qualitative study. <b>2019</b> , 16, 74	9
703	When and how do individuals transition from regular drug use to injection drug use in Uganda? Findings from a rapid assessment. <b>2019</b> , 16, 73	4
702	HIV/HCV co-infection and associated risk factors among injecting drug users in Dar es Salaam, Tanzania: potential for HCV elimination. <b>2019</b> , 16, 68	6
701	High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique. <b>2019</b> , 19, 1022	14
700	Evolving HIV epidemics: the urgent need to refocus on populations with risk. <b>2019</b> , 14, 337-353	15
699	Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. <b>2019</b> , 39, 20-30	49

698	What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats. <b>2019</b> , 156, 297-310	48
697	Subchronic ketamine alters behaviour, metabolic indices and brain morphology in adolescent rats: Involvement of oxidative stress, glutamate toxicity and caspase-3-mediated apoptosis. <b>2019</b> , 96, 22-33	17
696	Elimination of HIV transmission through novel and established prevention strategies among people who inject drugs. <b>2019</b> , 6, e128-e136	15
695	Medical complications of homelessness: a neglected side of men's health. <b>2019</b> , 49, 455-460	7
694	Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. <b>2019</b> , 194, 487-494	24
693	Intimate partner violence and receptive syringe sharing among women who inject drugs in Indonesia: A respondent-driven sampling study. <b>2019</b> , 63, 1-11	5
692	Mathematical modeling of hepatitis c virus (HCV) prevention among people who inject drugs: A review of the literature and insights for elimination strategies. <b>2019</b> , 481, 194-201	29
691	Public Health Considerations among People who Inject Drugs with HIV/HCV Co-Infection: A Review. <b>2019</b> , 8, 23-32	7
690	Development, validation, and potential applications of the hepatitis C virus injection-risk knowledge scale (HCV-IRKS) among young opioid users in New York City. <b>2019</b> , 194, 453-459	9
689	Use of Antiretroviral Drug Testing to Assess the Accuracy of Self-reported Data from HIV-Infected People Who Inject Drugs. <b>2019</b> , 23, 2101-2108	8
688	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. <b>2019</b> , 4, 135-184	216
687	Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysis. <b>2019</b> , 26, 236-245	11
686	Test uptake and hepatitis C prevalence in 5483 Danish people in drug use treatment from 1996 to 2015: a registry-based cohort study. <b>2019</b> , 114, 494-503	8
685	Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. <b>2019</b> , 70, 33-39	46
684	Improving hepatitis C direct-acting antiviral access and uptake: A role for patient-reported outcomes and lived experience. <b>2019</b> , 26, 218-223	6
683	Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system. <b>2019</b> , 38, 264-269	15
682	Comparing Injecting Risk Behaviors of Long-Term Injectors with New Injectors in Tehran, Iran. <b>2019</b> , 54, 185-190	6
681	Implementation of Syringe Services Programs to Prevent Rapid Human Immunodeficiency Virus Transmission in Rural Counties in the United States: A Modeling Study. <b>2020</b> , 70, 1096-1102	17

680	Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection. <b>2020</b> , 70, 123-131	4
679	Rapid Identification and Investigation of an HIV Risk Network Among People Who Inject Drugs -Miami, FL, 2018. <b>2020</b> , 24, 246-256	23
678	Hepatitis C Virus Prevalence and Incidence in a Large Nationwide Sample of Patients in Opioid Substitution Treatment in Germany: A Prospective Cohort Study. <b>2020</b> , 70, 2199-2205	2
677	Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study). <b>2020</b> , 115, 573-582	7
676	Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial. <b>2020</b> , 72, 67-74	15
675	Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population. <b>2020</b> , 70, 2652-2662	1
674	Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study. <b>2020</b> , 70, 2369-2376	8
673	Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada. <b>2020</b> , 110, 45-50	25
672	Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy. <b>2020</b> , 10,	11
671	Correlates of hepatitis C viral clustering among people who inject drugs in Baltimore. <b>2020</b> , 77, 104078	4
670	Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study. <b>2020</b> , 115, 901-913	11
669	Hepatitis C virus elimination in Indonesia: Epidemiological, cost and cost-effectiveness modelling to advance advocacy and strategic planning. <b>2020</b> , 40, 286-297	7
668	HIV prevalence among people who inject drugs (PWID) and related factors in Iran: a systematic review, meta-analysis and trend analysis. <b>2020</b> , 115, 605-622	19
667	Detachable low dead space syringes for the prevention of hepatitis C among people who inject drugs in Bristol, UK: an economic evaluation. <b>2020</b> , 115, 702-713	5
666	Transfusion-transmitted hepatitis C: A cluster of cases in transfusion-dependent thalassaemia patients in Sri Lanka. <b>2020</b> , 30, 377-383	1
665	Opioid use disorder. <b>2020</b> , 6, 3	95
664	Heroin Abuse and/or HIV Infection Dysregulate Plasma Exosomal miRNAs. <b>2020</b> , 15, 400-408	9
663	Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study. <i>The Lancet Global Health</i> , <b>2020</b> , 8, e244-e253	13.6 10

662	Effect of expanding opioid agonist therapies on the HIV epidemic and mortality in Ukraine: a modelling study. <b>2020</b> , 7, e121-e128	10
661	Prevalence of HIV/Hepatitis C Virus Co-Infection and Injection Risk Correlations in People Who Inject Drugs in Colombia: A Cross-Sectional Study Using Respondent Driven Sampling. <b>2020</b> , 55, 414-423	3
660	All-Cause and Cause-Specific Mortality Among People Using Extramedical Opioids: A Systematic Review and Meta-analysis. <b>2020</b> , 77, 493-502	23
659	Neurosurgical treatment for addiction: lessons from an untold story in China and a path forward. <b>2020</b> , 7, 702-712	9
658	Characterizing latent classes of social support among persons who inject drugs. <b>2020</b> , 207, 107816	2
657	The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities. <b>2020</b> , 34, 447-458	19
656	Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis. <i>The Lancet Global Health</i> , <b>2020</b> , 8, e76-e91	7
655	Depression, post-traumatic stress disorder, suicidality and self-harm among people who inject drugs: A systematic review and meta-analysis. <b>2020</b> , 207, 107793	17
654	Addressing Police Occupational Safety During an Opioid Crisis: The Syringe Threat and Injury Correlates (STIC) Score. <b>2020</b> , 62, 46-51	3
653	"Take Charge, Get Cured": Pilot testing a targeted mHealth treatment decision support tool for methadone patients with hepatitis C virus for acceptability and promise of efficacy. <b>2020</b> , 109, 23-33	2
652	Childhood abuse as a risk factor for injection drug use: A systematic review of observational studies. <b>2020</b> , 39, 71-82	4
651	Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. <b>2020</b> , 221, 1677-1687	48
650	Model-based cost-effectiveness estimates of testing strategies for diagnosing hepatitis C virus infection in people who use injecting drugs in Senegal. <b>2020</b> , 75, 102613	5
649	Time matters: Point of care screening and streamlined linkage to care dramatically improves hepatitis C treatment uptake in prisoners in England. <b>2020</b> , 75, 102608	15
648	Rates, knowledge and risk factors of non-fatal opioid overdose among people who inject drugs in India: A community-based study. <b>2020</b> , 39, 93-97	6
647	Assessment of Subjective Sleep Problems in Men With Opioid Dependence Maintained on Buprenorphine. <b>2020</b> , 14, 132-138	5
646	Record Linkage Approaches Using Prescription Drug Monitoring Program and Mortality Data for Public Health Analyses and Epidemiologic Studies. <b>2020</b> , 31, 22-31	7
645	Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis. <b>2020</b> , 115, 1413-1425	7

644	Frequency of injecting among people who inject drugs: A systematic review and meta-analysis. <b>2020</b> , 76, 102619	9
643	Clinical and Patient-Reported Outcomes of Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C Among Patients on Opioid Agonist Treatment: A Real-world Prospective Cohort Study. <b>2020</b> , 7, ofaa317	2
642	Low Adherence Achieves High HCV Cure Rates Among People Who Inject Drugs Treated With Direct-Acting Antiviral Agents. <b>2020</b> , 7, ofaa377	4
641	Prevalence of Common Mental Disorders in South Asia: A Systematic Review and Meta-Regression Analysis. <b>2020</b> , 11, 573150	8
640	Initial Heroin Use Patterns Predict 5-Year Relapse: Results from a Longitudinal Cohort Study in Shanghai, China. <b>2020</b> , 1	
639	Injecting risk behaviours amongst people who inject drugs: A global multi-stage systematic review and meta-analysis. <b>2020</b> , 84, 102866	5
638	Spatial epidemiology: An empirical framework for syndemics research. <b>2020</b> , 295, 113352	5
637	Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. <b>2020</b> , 5, 809-818	24
636	Targeted Outreach, Education, and Point-of-Care Testing for HIV and Hepatitis C: Strategies to Address HIV Infection in Marginalized Communities in Vancouver. <b>2020</b> , 34, 281-283	1
635	Hepatitis B virus infection among people who use drugs in Iran: a systematic review, meta-analysis, and trend analysis. <b>2020</b> , 17, 81	5
634	Challenges facing harm reduction interventions in the era of COVID-19 in Africa. <b>2020</b> , 9, e00506	4
633	Achieving Hepatitis C Elimination By Using Person-Centered, Nurse-Led Models of Care: A Discussion of Four International Case Studies. <b>2020</b> , 43, 303-309	2
632	Human Immunodeficiency Virus Testing, Diagnosis, Linkage to Care, and Prevention Services Among Persons Who Inject Drugs, United States, 2012-2017. <b>2020</b> , 222, S268-S277	0
631	Getting to the point: Methamphetamine injection is associated with biomarkers relevant to HIV pathogenesis. <b>2020</b> , 213, 108133	5
630	Keynote Address 2018 Southern Maine Harm Reduction Conference. <b>2020</b> , 41, 905-912	
629	Outcomes of Surgical and Endovascular Treatment for Arterial Lesions in Intravenous Drug Abusers. <b>2020</b> , 69, 133-140	0
628	A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report. <b>2020</b> , 17, 49	17
627	The Copenhagen test and treat hepatitis C in a mobile clinic study: a protocol for an intervention study to enhance the HCV cascade of care for people who inject drugs (T'N'T HepC). <b>2020</b> , 10, e039724	2

626	Distance matters: The association of proximity to syringe services programs with sharing of syringes and injecting equipment - 17 U.S. cities, 2015. <b>2020</b> , 85, 102923	3
625	Assisted injection provider practices and motivations in Los Angeles and San Francisco California 2016-18. <b>2021</b> , 92, 103052	2
624	Optimizing Hepatitis C Virus (HCV) Treatment in a US Colocated HCV/Opioid Agonist Therapy Program. <b>2020</b> , 7, ofaa310	4
623	Applying the Infectious Diseases Literature to People who Inject Drugs. <b>2020</b> , 34, 539-558	6
622	Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018. <b>2020</b> , 23, 1137-1141	7
621	Invasive group A streptococcal infections in North West England: epidemiology, risk factors and fatal infection. <b>2020</b> , 186, 63-70	2
620	Epidemics of HIV Infection among Heavy Drug Users of Depressants Only, Stimulants Only, and Both Depressants and Stimulants in Mainland China: A Series, Cross-Sectional Studies. <b>2020</b> , 17,	1
619	Prevalence and management of tuberculosis among people who use drugs in Abidjan, Ivory Coast. <b>2020</b> , 83, 102862	1
618	Colocalization in Hepatitis C Virus Infection Care: The Role of Opioid Agonist Therapy Clinics. <b>2020</b> , 16, 12-15	
617	Impact of routine opt-out HIV/HCV screening on testing uptake at a syringe services program: An interrupted time series analysis. <b>2020</b> , 84, 102875	8
616	Anticipated use of a supervised drug consumption site among syringe services program clients in King County, Washington: Assessing the role of opioid overdose and injection behavior. <b>2020</b> , 213, 108121	3
615	Challenges posed by COVID-19 to people who inject drugs and lessons from other outbreaks. <b>2020</b> , 23, e25583	61
614	Development of a global index measuring national policy commitments to HIV prevention and treatment among people who inject drugs. <b>2020</b> , 84, 102877	3
613	Perspectives of clients and providers on factors influencing opioid agonist treatment uptake among HIV-positive people who use drugs in Indonesia, Ukraine, and Vietnam: HPTN 074 study. <b>2020</b> , 17, 69	2
612	Not Just Endocarditis: Hospitalizations for Selected Invasive Infections Among Persons With Opioid and Stimulant Use Diagnoses-North Carolina, 2010-2018. <b>2020</b> , 222, S458-S464	4
611	Prevalence of and risk factors for HBV and HCV among incarcerated people who inject drugs in Iran: A cross sectional study. <b>2020</b> , 20, 806	1
610	Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy. <b>2020</b> , 83, 102837	5
609	On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017. <b>2020</b> , 10, e036355	2

608	Can use any syringe I find contextual determinants of HIV risk in public injecting settings in Nigeria. <b>2020</b> , 20, 371-381	2
607	A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South. <b>2020</b> , 17, 64	5
606	Population Size Estimate of Men Who Have Sex With Men, Female Sex Workers, and People Who Inject Drugs in Mozambique: A Multiple Methods Approach. <b>2020</b> , 47, 602-609	3
605	EASL recommendations on treatment of hepatitis C: Final update of the series. <b>2020</b> , 73, 1170-1218	237
604	Substance use service availability in HIV treatment programs: Data from the global IeDEA consortium, 2014-2015 and 2017. <b>2020</b> , 15, e0237772	3
603	Addressing treatment and care needs of older adults living with HIV who use drugs. <b>2020</b> , 23, e25577	0
602	Has resourcing of non-governmental harm-reduction organizations in Ukraine improved HIV prevention and treatment outcomes for people who inject drugs? Findings from multiple bio-behavioural surveys. <b>2020</b> , 23, e25608	3
601	HCV micro-elimination in two prisons in Milan, Italy: A model of care. <b>2020</b> , 27, 1444-1454	7
600	Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis. <b>2020</b> , 15, 64	9
599	An update on drug-drug interactions between antiretroviral therapies and drugs of abuse in HIV systems. <b>2020</b> , 16, 1005-1018	4
598	Pathogen influence on epidemiology, diagnostic evaluation and management of infective endocarditis. <b>2020</b> , 106, 1878-1882	7
597	Prevalence and recurrence of bacteraemia in hospitalised people who inject drugs - a single Centre retrospective cohort study in Denmark. <b>2020</b> , 20, 634	0
596	Emerging Viral and Bacterial Infections: Within an Era of Opioid Epidemic. <b>2020</b> , 9, 737-755	
595	Migration experiences, life conditions, and drug use practices of Russian-speaking drug users who live in Paris: a mixed-method analysis from the ANRS-Coquelicot study. <b>2020</b> , 17, 55	1
594	Prevalence of Chronic Hepatitis B Virus Infection in the United States. <b>2020</b> , 115, 1429-1438	32
593	Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017). <b>2020</b> , 20, 655	11
592	Life expectancy of people who are dependent on opioids: A cohort study in New South Wales, Australia. <b>2020</b> , 130, 435-440	3
591	Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study. <b>2021</b> , 73, e3661-e3669	16



590	Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities. <b>2020</b> , 222, S301-S311	0
589	Long-term durability of immunogenicity induced by standard and triple-dose hepatitis B vaccine in patients receiving methadone maintenance treatment. <b>2020</b> , 19, 785-794	
588	Harm reduction via online platforms for people who use drugs in Russia: a qualitative analysis of web outreach work. <b>2020</b> , 17, 98	4
587	Impact of clinical and sociodemographic factors on fatigue among patients with substance use disorder: a cohort study from Norway for the period 2016-2020. <b>2020</b> , 15, 93	1
586	Sex differences in the multilevel determinants of injection risk behaviours among people who inject drugs in Tijuana, Mexico. <b>2020</b> , 39, 898-907	0
585	Women and barriers to harm reduction services: a literature review and initial findings from a qualitative study in Barcelona, Spain. <b>2020</b> , 17, 78	11
584	Putting a roof over people's heads: an important part of addressing HCV infection among people who inject drugs. <b>2020</b> , 15, 253-255	
583	Non-fatal overdose among people who inject drugs in Tehran, Iran. <b>2020</b> , 15, 80	6
582	Association of Violence Against Female Sex Workers Who Use Drugs With Nonfatal Drug Overdose in Kazakhstan. <b>2020</b> , 3, e2020802	8
581	The impact of the COVID-19 pandemic on harm reduction services in Spain. <b>2020</b> , 17, 87	15
580	Risk of hepatitis C virus infection in injecting and noninjecting drug users receiving opioid substitution therapy. <b>2020</b> , 83, 454-460	1
579	The gut microbiome and frailty. <b>2020</b> , 221, 23-43	9
578	The fentanyl epidemic in Estonia: factors in its evolution and opportunities for a comprehensive public health response, a scoping review. <b>2020</b> , 81, 102757	7
577	Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. <b>2020</b> , 17, 26	111
576	Viral hepatitis in patients on hemodialysis. <b>2020</b> , 33, 254-262	0
575	Estimating the prevalence of problem drug use from drug-related mortality data. <b>2020</b> , 115, 2393-2404	11
574	Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis. <b>2020</b> , 36, 1325-1332	3
573	Challenges for hepatitis B virus cure in resource-limited settings in sub-Saharan Africa. <b>2020</b> , 15, 185-192	2

572	Systematic Review and Meta-Analysis of Global Prevalence of HBsAg and HIV and HCV Antibodies among People Who Inject Drugs and Female Sex Workers. <b>2020</b> , 9,	12
571	Prevalence and risk factors associated with HIV/hepatitis B and HIV/hepatitis C co-infections among people who inject drugs in Mozambique. <b>2020</b> , 20, 851	4
570	High prevalence of injection drug use and blood-borne viral infections among patients in an urban emergency department. <b>2020</b> , 15, e0233927	6
569	Relationship between social capital and heroin use behaviors among patients in methadone maintenance treatment in Sichuan Province, China: A cross-sectional study. <b>2020</b> , 99, e19963	3
568	Factors associated with HIV testing among people who inject drugs: a meta-analysis. <b>2020</b> , 38, 361-374	14
567	Opioid use disorder and infectious complications in persons who inject drugs. <b>2020</b> , 58, 4-11	3
566	Management of dependent use of illicit opioids. <b>2020</b> , 368, m710	1
565	How far is Mexico from Viral Hepatitis Global Health Sector Strategy 2030 targets. <b>2020</b> , 19, 123-125	4
564	Predictors of long-term retention on opioid agonist treatment with buprenorphine: a 6-year, community-based retrospective cohort study in India. <b>2020</b> , 25, 489-494	
563	Validity of ICD-based algorithms to estimate the prevalence of injection drug use among infective endocarditis hospitalizations in the absence of a reference standard. <b>2020</b> , 209, 107906	6
562	High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients. <b>2020</b> , 72, 1028-1029	4
561	Exposure to HIV risks among young people who use drugs (YPUD) in three cities in Vietnam: time to develop targeted interventions. <b>2020</b> , 17, 13	5
560	Baseline prevalence and correlates of HIV and HCV infection among people who inject drugs accessing a syringe services program; Miami, FL. <b>2020</b> , 17, 40	9
559	Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. <b>2020</b> , 15, 44	4
558	Challenges and Strategies for Access to Treatment of Hepatitis C in Latin America. <b>2020</b> ,	0
557	COVID-19 - Enacting a 'new normal' for people who use drugs. <b>2020</b> , 83, 102832	28
556	Acupuncture combined with medication for opioid use disorder in adults: a protocol for systematic review and meta-analysis. <b>2020</b> , 10, e034554	2
555	Access to and use of health and social services among people who inject drugs in two urban areas of Mozambique, 2014: qualitative results from a formative assessment. <b>2020</b> , 20, 975	5

554	Factors associated with injecting-related risk behaviors among people who inject drugs: a systematic review and meta-analysis study. <b>2020</b> , 38, 420-437	15
553	Global prevalence of HCV and/or HBV coinfections among people who inject drugs and female sex workers who live with HIV/AIDS: a systematic review and meta-analysis. <b>2020</b> , 165, 1947-1958	8
552	The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa. <b>2020</b> , 115, 1244-1262	8
551	Economic Evaluation of Hepatitis C Treatment Extension to Acute Infection and Early-Stage Fibrosis Among Patients Who Inject Drugs in Developing Countries: A Case of China. <b>2020</b> , 17,	3
550	The changing modes of human immunodeficiency virus transmission and spatial variations among women in a minority prefecture in southwest China: An exploratory study. <b>2020</b> , 99, e18776	2
549	Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs. <b>2020</b> , 71, 1715-1722	43
548	High prevalence of human immunodeficiency virus, hepatitis B and C viral infections among people who inject drugs: a potential stumbling block in the control of HIV and viral hepatitis in Tanzania. <b>2020</b> , 20, 177	3
547	Time for the Elimination of Hepatitis C Virus as a Global Health Threat. <b>2020</b> , 935-952	1
546	A vulnerability assessment for the HCV infections associated with injection drug use. <b>2020</b> , 134, 106040	5
545	Significant decrease in injection risk behaviours among participants in a needle exchange programme. <b>2020</b> , 52, 336-346	10
544	Understanding HIV risk and vulnerability among cisgender men with transgender partners. <b>2020</b> , 7, e201-e208	12
543	Prevalence of HCV among people who inject drugs in Brussels-a respondent-driven sampling survey. <b>2020</b> , 17, 11	3
542	Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review. <b>2020</b> , 209, 107899	1
541	Validation of hepatitis C virus RNA detection using capillary blood by finger prick (GenXpert system)-Hepatitis C fingerprick study. <b>2020</b> , 27, 709-714	6
540	The HIV epidemic in Latin America: a time to reflect on the history of success and the challenges ahead. <b>2020</b> , 23, e25468	6
539	Infectious diseases occurring in the context of substance use disorders: A concise review. <b>2020</b> , 411, 116719	4
538	Hepatitis C virus infection in people who inject drugs in Africa. <b>2020</b> , 20, 283-284	0
537	Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population. <b>2020</b> , 40, 787-796	6

536	Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care. <b>2020</b> , 27, 663-670	8
535	WITHDRAWN: The next frontier: universal hepatitis C virus screening in pregnant women. <b>2020</b> ,	
534	Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence. <b>2020</b> , 77, 102656	5
533	Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England. <b>2020</b> , 115, 1509-1521	3
532	High-risk behaviors and their association with awareness of HIV status among participants of a large-scale prevention intervention in Athens, Greece. <b>2020</b> , 20, 105	4
531	Puerto Rican Syndemics: Opiates, Overdoses, HIV, and the Hepatitis C Virus in a Context of Ongoing Crises. <b>2020</b> , 110, 176-177	10
530	Polyvictimization and depression as predictors of HIV risk behaviors among juvenile offenders. <b>2020</b> , 29, 1013	1
529	Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial. <b>2020</b> , 3, e151	2
528	Recent incarceration and risk of first-time injection initiation assistance: A prospective cohort study of persons who inject drugs. <b>2020</b> , 212, 107983	3
527	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. <b>2020</b> , 119, 1135-1157	34
526	Navigating environmental constraints to injection preparation: the use of saliva and other alternatives to sterile water among unstably housed PWID in London. <b>2020</b> , 17, 24	13
525	Advantages of Outpatient Treatment with Long-Acting Lipoglycopeptides for Serious Gram-Positive Infections: A Review. <b>2020</b> , 40, 469-478	15
524	HIV control programs reduce HIV incidence but not HCV incidence among people who inject drugs in HaiPhong, Vietnam. <b>2020</b> , 10, 6999	7
523	Contribution of Behavioral Health Factors to Non-AIDS-Related Comorbidities: an Updated Review. <b>2020</b> , 17, 354-372	5
522	Gender-based vulnerability in women who inject drugs in a harm reduction setting. <b>2020</b> , 15, e0230886	9
521	Young people who inject drugs in Mozambique: should we emphasize them in the National Harm Reduction Plan?. <b>2020</b> , 17, 20	4
520	The Elimination of Hepatitis C as a Public Health Threat. <b>2020</b> , 10,	2
519	Commentary on Krawczyk et al. (2020): Reinforcing the case for evidence-based treatment of opioid use disorder. <b>2020</b> , 115, 1695-1696	

518	Injection and sexual risk among people who use or inject drugs in Kampala, Uganda: An exploratory qualitative study. <b>2020</b> , 15, e0231969	3
517	Epidemiology of Alcohol Misuse and Illicit Drug Use Among Young People Aged 15-24 Years in Fishing Communities in Uganda. <b>2020</b> , 17,	9
516	Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky. <b>2021</b> , 88, 102707	1
515	Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis. <b>2021</b> , 88, 102710	3
514	Geographic Shifts in Antibacterial Drug Clinical Trial Enrollment: Implications for Generalizability. <b>2021</b> , 72, 1422-1428	4
513	Prevalence and correlates of receptive syringe-sharing among people who inject drugs in rural Appalachia. <b>2021</b> , 116, 328-336	3
512	Outcomes of femoral artery ligation for treatment of infected femoral pseudoaneurysms due to drug injection. <b>2021</b> , 73, 635-640	3
511	Hospital Costs of Injection Drug Use in Florida. <b>2021</b> , 72, 499-502	9
510	Sometimes I feel like the other life on heroin was better—transitioning experiences towards methadone, and HIV prevention implications in Urban Kenya. <b>2021</b> , 28, 246-254	
509	Modeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States. <b>2021</b> , 72, 755-763	3
508	Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta-analysis. <b>2021</b> , 116, 1664-1676	2
507	Effects of dopamine D1- and D2-like receptors in the CA1 region of the hippocampus on expression and extinction of morphine-induced conditioned place preference in rats. <b>2021</b> , 397, 112924	4
506	Anterior Cingulate Cortex in Addiction: New Insights for Neuromodulation. <b>2020</b> , 24, 187	7
505	Design, implementation, and monitoring of HIV service packages for people who inject drugs: An assessment of programs supported by the Global Fund in 46 countries. <b>2021</b> , 88, 103036	0
504	The cost of a late-detected outbreak among people who inject drugs. A modeling study. <b>2021</b> , 88, 103032	1
503	Acceptance and commitment therapy for treatment of stigma and shame in substance use disorders: a double-blind, parallel-group, randomized controlled trial. <b>2021</b> , 26, 413-419	1
502	Increasing hepatitis C testing and linkage to care: Results of a testing campaign with incentives at primary care clinics in Melbourne, Australia. <b>2021</b> , 28, 569-572	4
501	Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis. <b>2021</b> , 6, 39-56	17

500	Estimates of people who injected drugs within the last 12 months in Belgium based on a capture-recapture and multiplier method. <b>2021</b> , 219, 108436	0
499	Commentary on Hamilton White et al. : Receptive syringe-sharing among people who inject drugs in rural settings. <b>2021</b> , 116, 337-338	
498	Drug Injection-Related Norms and High-Risk Behaviors of People Who Inject Drugs in Athens, Greece. <b>2021</b> , 37, 130-138	3
497	Food insecurity among people who inject drugs in Athens, Greece: a study in the context of ARISTOTLE programme. <b>2021</b> , 24, 813-818	
496	Alcohol Use Disorder and Hepatitis C Prevention and Care in People Who Inject Drugs: The State of Play. <b>2021</b> , 41, 109-116	1
495	Self-perception of assisting with future injection drug initiation: The influence of relationships in the process of drug injecting initiation. <b>2021</b> , 40, 109-117	2
494	Provider Perspectives on Integration of Substance Use Disorder and HIV Care in Vietnam: A Qualitative Study. <b>2021</b> , 48, 274-286	3
493	"Health Is on the Back Burner:" Multilevel Barriers and Facilitators to Primary Care Among People Who Inject Drugs. <b>2021</b> , 36, 129-137	18
492	Seroprevalence of hepatitis B and associated factors among inmates: a cross sectional study in the Douala New Bell Prison, Cameroon. <b>2021</b> , 38, 355	1
491	Endogenous endophthalmitis in patients with intravenous opioid use: demographics and associated comorbidities. <b>2021</b> , 41, 1513-1520	0
490	The case of Scott County: injection drug use and the HIV and hepatitis C virus outbreak. <b>2021</b> , 11-24	
489	Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China. <b>2021</b> , 16, e0245288	2
488	Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection. <b>2021</b> , 9, 125-132	1
487	HCV elimination in Hong Kong - Non-government organisation (NGO) activities. <b>2021</b> , 3, 283-287	0
486	Substances detected in used syringes of injecting drug users across 7 cities in Europe in 2017 and 2018: The European Syringe Collection and Analysis Project Enterprise (ESCAPE). <b>2021</b> , 95, 103130	7
485	Predictors of Willingness to Diffuse PrEP Information within Ego-Centric Networks of Women Who Inject Drugs. <b>2021</b> , 25, 1856-1863	2
484	Epidemiology of Hepatitis C Virus: People Who Inject Drugs and Other Key Populations. <b>2021</b> , 109-149	
483	Comparing right- and left sided injection-drug related infective endocarditis. <b>2021</b> , 11, 1177	4

- 482 Drug addiction profile and monitoring liver functions tests of addicts at a specialized psychiatric treatment center. **2021**, 5, 55-60
- 481 Prevention: Secondary Prevention and Screening. **2021**, 189-199
- 480 Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis. **2021**, 18, 12 1
- 479 Modeling the impact of harm reduction for opioid use disorder on infectious disease prevention. **2021**, 247-274
- 478 Viral hepatitis C pandemic: Challenges and threats to its elimination. **2021**, 28, 694-698 1
- 477 Young and invisible: an explanatory model for service engagement by people who inject drugs in India.
- 476 Correlates of injection-related wounds and skin infections amongst persons who inject drugs and use a syringe service programme: A single center study. **2021**, 18, 701-707 3
- 475 The performance of hepatitis C virus (HCV) antibody point-of-care tests on oral fluid or whole blood and dried blood spot testing for HCV serology and viral load among individuals at higher risk for HCV in South Africa. **2021**, 4, e229 2
- 474 Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree. **2021**, 27, 137-146 2
- 473 Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience. **2021**, 116, 1248-1255 2
- 472 Computer-based alcohol reduction intervention for alcohol-using HIV/HCV co-infected Russian women in clinical care: study protocol for a randomized controlled trial. **2021**, 22, 147
- 471 Initiation of Low-threshold Buprenorphine in Nontreatment Seeking Patients With Opioid Use Disorder Engaged in Hepatitis C Treatment. **2021**, 1
- 470 Outcomes of Femoral Artery Pseudoaneurysm in Intravenous Drug Abusers Managed at a Tertiary Care Center. **2021**, 13, e13350
- 469 Chronic morphine administration differentially modulates viral reservoirs in SIVmac251 infected rhesus macaque model. **2020**, 6
- 468 Community Led Testing among People Who Inject Drugs: A community centered model to find new cases of HIV and Hepatitis C in Nepal.
- 467 Barriers to HIV and Hepatitis C care for people who inject drugs in Colombia. **2021**, 1-6 1
- 466 Hepatitis C Virus Prevalence, Screening, and Treatment Among People Who Are Incarcerated in Canada: Leaving No One Behind in the Direct-Acting Antiviral Era. **2021**, 17, 75-80 3
- 465 2021 European guideline on HIV testing in genito-urinary medicine settings. **2021**, 35, 1043-1057 0

464	Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico. <b>2021</b> , 116, 2734-2745	1
463	"I want to get better, but...": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments. <b>2021</b> , 20, 81	1
462	Prevalence of high-risk drug use and coverage of opioid substitution treatment and needle and syringe programs in Lithuania in 2015-2016: A multi-method estimation study. <b>2021</b> , 122, 108229	0
461	Prevalence of HIV, HCV and HBV in Central Asia and the Caucasus: A systematic review. <b>2021</b> , 104, 510-525	6
460	Association Between Chronic Hepatitis C Virus Infection and Esophageal Cancer: A Systematic Review and Meta-analysis. <b>2022</b> , 56, 55-63	2
459	Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study. <b>2021</b> , 6, 169-184	5
458	Recent HIV testing and associated factors among people who use drugs in Cambodia: a national cross-sectional study. <b>2021</b> , 11, e045282	1
457	HIV Injection Risk Behaviors among HIV-Negative People Who Inject Drugs Experiencing Homelessness, 23 U.S. Cities. <b>2020</b> , 1,	0
456	Examining common mental health disorders in people living with HIV on methadone maintenance therapy in Hanoi, Vietnam. <b>2021</b> , 18, 45	2
455	Hepatitis C virus micro-elimination: Where do we stand?. <b>2021</b> , 27, 1728-1737	1
454	Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy. <b>2021</b> , 28, 878-886	
453	Prevalence of HIV, viral hepatitis B/C and tuberculosis and treatment outcomes among people who use drugs: Results from the implementation of the first drop-in-center in Mozambique. <b>2021</b> , 90, 103095	2
452	Snapshot of narcotic drugs and psychoactive substances in Kuwait: analysis of illicit drugs use in Kuwait from 2015 to 2018. <b>2021</b> , 21, 671	1
451	Application of the frailty framework among vulnerable populations to hospitalization outcomes of individuals experiencing homelessness in Long Beach, California. 1-9	0
450	"PrEP just isn't my priority": Adherence challenges among women who inject drugs participating in a pre-exposure prophylaxis (PrEP) demonstration project in Philadelphia, PA USA. <b>2021</b> , 275, 113809	3
449	Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis. <b>2021</b> , 8, 301-309	6
448	A Syringe Service Program Within a Federal System: Foundations for Implementation. <b>2021</b> , 32, 152-158	
447	Proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure HIV and HCV incidence in Kerman, Iran. <b>2021</b> , 16, 29	0



446	Reducing police occupational needle stick injury risk following an interactive training: the SHIELD cohort study in Mexico. <b>2021</b> , 11, e041629	3
445	A prospective cohort study of risk behaviours, retention and loss to follow-up over 5 years among women and men in a needle exchange program in Stockholm, Sweden. <b>2021</b> , 90, 103059	0
444	Homelessness, HIV testing, and the reach of public health efforts for people who inject drugs, San Francisco, California. <b>2021</b> , 221, 108560	1
443	Surgical treatment of infective endocarditis in intravenous drug abusers. <b>2021</b> , 16, 97	1
442	Rapid point-of-care (POC) testing for Hepatitis C antibodies in a very high prevalence setting: persons injecting drugs in Tallinn, Estonia. <b>2021</b> , 18, 39	2
441	Dopamine Levels Induced by Substance Abuse Alter Efficacy of Maraviroc and Expression of CCR5 Conformations on Myeloid Cells: Implications for NeuroHIV. <b>2021</b> , 12, 663061	2
440	Infective endocarditis in an intravenous drug user: multiple fatal complications. <b>2021</b> , 14,	
439	HIV treatment outcomes among people who acquired HIV via injecting drug use in the Asia-Pacific region: a longitudinal cohort study. <b>2021</b> , 24, e25736	0
438	Human Immunodeficiency Virus and Hepatitis C Linkage-to-Care Initiative for New Orleans Residents Experiencing Homelessness During the COVID-19 Pandemic. <b>2021</b> , 48, 595-600	1
437	Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China. <b>2021</b> , 9, 419-427	1
436	Treatment of opioid use disorder in primary care. <b>2021</b> , 373, n784	6
435	Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. <b>2021</b> , 6, e309-e323	30
434	Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020. <b>2021</b> , 5, 911-922	7
433	Community led testing among people who inject drugs: A community centered model to find new cases of HIV and Hepatitis C in Nepal. <b>2021</b> , 16, e0252490	
432	Substances use disorders and liver injury: a concise review. <b>2021</b> ,	1
431	Sociometric Risk Network Structure, HIV Prevalence, and Drug Injection-Related Norms among People Who Inject Drugs (PWID) in Athens, Greece. <b>2021</b> , 56, 1190-1201	1
430	Serious games in preventing sexually transmitted infections among adolescents: Systematic review about the current state of evidence (Preprint).	
429	The effect of needle and syringe program and opioid agonist therapy on the risk of HIV, hepatitis B and C virus infection for people who inject drugs in Amsterdam, the Netherlands: findings from an emulated target trial. <b>2021</b> , 116, 3115-3126	3

428	"You need money to get high, and that's the easiest and fastest way." A typology of sex work and health behaviours among people who inject drugs. <b>2021</b> , 96, 103285	1
427	HIV incidence and associated risk factors in female spouses of men who inject drugs in Pakistan. <b>2021</b> , 18, 51	0
426	The Influence of PrEP-Related Stigma and Social Support on PrEP-Use Disclosure among Women Who Inject Drugs and Social Network Members. <b>2021</b> , 25, 3922-3932	1
425	Is Drug Use-Associated Endocarditis a Social Disease?: Reply. <b>2021</b> , 111, 1737	
424	Global Epidemiology of Chronic Liver Disease. <b>2021</b> , 17, 365-370	24
423	A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. <b>2021</b> , 14, 139-156	1
422	Mobile low-threshold buprenorphine integrated with infectious disease services. <b>2021</b> , 108553	2
421	Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction-A Real-world Experience. <b>2021</b> , 8, ofab325	0
420	The state of harm reduction in prisons in 30 European countries with a focus on people who inject drugs and infectious diseases. <b>2021</b> , 18, 67	1
419	Therapy of chronic hepatitis C in people who inject drugs: focus on adherence. <b>2021</b> , 18, 69	2
418	Ongoing HIV transmission following a large outbreak among people who inject drugs in Athens, Greece (2014-2020).	1
417	Us for us: reflections of a journey by people who use drugs in East Africa to shape HIV, hepatitis and other relevant health policies. <b>2021</b> , 24 Suppl 3, e25730	0
416	Attributing health benefits to preventing HIV infections versus improving health outcomes among people living with HIV: an analysis in six US cities. <b>2021</b> , 35, 2169-2179	
415	The impact of current opioid agonist therapy on hepatitis C virus treatment initiation among people who use drugs from in the DAA era: A population-based study. <b>2021</b> ,	0
414	New hepatitis C virus infection, re-infection and associated risk behaviour in male Irish prisoners: a cohort study, 2019. <b>2021</b> , 79, 97	1
413	Factors Associated with Likelihood of Initiating Others into Injection Drug Use Among People Who Inject Drugs in West Virginia. <b>2021</b> , 1	1
412	Can hepatitis C elimination targets be sustained among people who inject drugs post-2030?. <b>2021</b> , 96, 103343	1
411	Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal. <b>2021</b> , 4, e290	1

410	Epidemic of HIV infection among persons who inject drugs in mainland China: a series, cross-sectional study. <b>2021</b> , 18, 63	3
409	Illicit Drug Use in Canada and Implications for Suicidal Behaviors, and Household Food Insecurity: Findings from a Large, Nationally Representative Survey. <b>2021</b> , 18,	2
408	HCV screening based on dried blood samples and linkage to care in people who use drugs: A prospective study. <b>2021</b> , 92, 103134	2
407	Factors associated with methamphetamine withdrawal symptoms among people who inject drugs. <b>2021</b> , 223, 108702	4
406	Mortality among amphetamine users with hepatitis C virus infection: A nationwide study. <b>2021</b> , 16, e0253710	0
405	A Feasibility Study to Increase Chronic Hepatitis C Virus RNA Testing and Linkage to Care among Clients Attending Homeless Services in Amsterdam, The Netherlands. <b>2021</b> , 11,	0
404	Evaluation of the scale-up of HIV testing among people who inject drugs in Scotland in the context of an ongoing HIV outbreak. <b>2021</b> , 96, 103304	1
403	Municipal police support for harm reduction services in officer-led referrals of people who inject drugs in Tijuana, Mexico. <b>2021</b> , 18, 76	2
402	Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency. <b>2021</b> , 13,	2
401	Hepatitis C Diagnosis: Simplified Solutions, Predictive Barriers, and Future Promises. <b>2021</b> , 11,	9
400	Beyond the Magic Bullet: What Will It Take to End the AIDS Epidemic?. <b>2021</b> , 111, 1234-1236	
399	The impact of direct-acting antivirals on hepatitis C viraemia among people who inject drugs in England; real-world data 2011-2018. <b>2021</b> , 28, 1452-1463	1
398	Utilizing patient perception of group treatment in exploring medication adherence, social support, and quality of life outcomes in people who inject drugs with hepatitis C. <b>2021</b> , 126, 108459	
397	PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. <b>2021</b> , 109, 174-200	7
396	Distribution of HCV Genotypes Among People Who Inject Drugs in Tunisia: New Evidence for Scaling Up Prevention and Treatment Toward National Elimination Goal. <b>2021</b> , 12, 697859	
395	Seroprevalence of hepatitis B virus infection, anti-HCV antibodies and HIV and knowledge among people who use drugs attending methadone therapy clinic in Tanzania; a cross-sectional study. <b>2021</b> , 21, 699	0
394	Barriers to hepatitis C treatment among secondary needle and syringe program clients and opportunities to intervene. <b>2021</b> , 96, 103387	2
393	Determinants of HIV-1 Late Presentation in Patients Followed in Europe. <b>2021</b> , 10,	5

392	An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis. <b>2021,</b>	1
391	Screening at a Federally Qualified Health Center in the Midwest for Hepatitis C Among People Who Inject Drugs, 2019-2020. <b>2021, 18, E69</b>	0
390	A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment. <b>2021, 96, 103359</b>	0
389	Involvement of people who inject drugs in injection initiation events: a cross-sectional analysis identifying similarities and differences across three North American settings. <b>2021, 11, e046957</b>	
388	Socioeconomic stability is associated with lower injection frequency among people with distinct trajectories of injection drug use. <b>2021, 94, 103205</b>	3
387	Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study. <b>2021, 96, 103421</b>	1
386	HIV screening and retention in care in people who use drugs in Madrid, Spain: a prospective study. <b>2021, 10, 111</b>	0
385	Reduction in injection risk behaviors after implementation of a syringe services program, Miami, Florida. <b>2021, 127, 108344</b>	0
384	Prevalence and correlates of non-fatal overdose among people who use drugs: findings from rapid assessments in Massachusetts, 2017-2019. <b>2021, 18, 93</b>	2
383	The Melbourne Safe Injecting Room Attracted People Most in Need of Its Service. <b>2021, 61, 217-224</b>	6
382	Co-receptor signaling in the pathogenesis of neuroHIV. <b>2021, 18, 24</b>	2
381	Opioid use disorder and the brain: a clinical perspective. <b>2021,</b>	1
380	Ingenuity and resiliency of syringe service programs on the front lines of the opioid overdose and COVID-19 crises. <b>2021, 234, 159-173</b>	8
379	Diversity of incarceration patterns among people who inject drugs and the association with incident hepatitis C virus infection. <b>2021, 96, 103419</b>	0
378	The Needle and the Damage Done: A Retrospective Review of the Health Impact of Recreational Intravenous Drug Use and the Collateral Consequences for Vascular Surgery. <b>2021,</b>	1
377	Participation in methadone programs improves antiretroviral uptake and HIV viral suppression among people who inject drugs in Kenya. <b>2021, 108587</b>	2
376	Hooked on the needle—Exploring the paradoxical attractions towards injecting drug use. 1-8	1
375	Treatment challenges and health conditions among people living with HIV with or without substance use disorder in the Russian Federation. <b>2021, 1-6</b>	1

374	Client characteristics associated with desire for additional services at syringe exchange programs. 1-7	
373	Planning the hepatitis C virus elimination in Cyprus: A modeling study. <b>2021</b> , 27, 5219-5231	
372	The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R). <b>2021</b> , 28, 1474-1483	0
371	"Sobriety equals getting rid of hepatitis C": A qualitative study exploring the interplay of substance use disorder and hepatitis C among hospitalized adults. <b>2021</b> , 127, 108337	1
370	Assessing HIV and overdose risks for people who use drugs exposed to compulsory drug abstinence programs (CDAP): A systematic review and meta-analysis. <b>2021</b> , 96, 103401	0
369	Decisional considerations for methadone uptake in Kyrgyz prisons: The importance of understanding context and providing accurate information. <b>2021</b> , 94, 103209	3
368	Detection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spain. <b>2021</b> , 96, 103424	0
367	Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons. <b>2021</b> , 74, 2366-2379	5
366	Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison. <b>2021</b> , 96, 103394	1
365	Injection Drug use Practices and HIV infection among People Who Inject Drugs in Kigali, Rwanda.	0
364	The impact of recent homelessness on the provision of injection drug use initiation assistance among persons who inject drugs in Tijuana, Mexico and Vancouver, Canada. <b>2021</b> , 225, 108829	2
363	Primary Care Associated With Follow Up Viral Load Testing in Patients Cured of Hepatitis C Infection With Direct Acting Antivirals at a Multidisciplinary Addiction Treatment Program: Insights From a Real-World Setting. <b>2021</b> ,	0
362	Risk factors for loss to follow-up of persons who inject drugs enrolled at syringe services programs in Kentucky. <b>2021</b> , 95, 103255	0
361	Peer-delivered services for substance use in low- and middle-income countries: A systematic review. <b>2021</b> , 95, 103252	3
360	Effectiveness of an HIV care model integrated into addiction care based on medication-assisted treatment for HIV-positive people who use drugs. <b>2021</b> , 1-8	0
359	Injection and Non-Injection Drug Use Among Adults with Diagnosed HIV in the United States, 2015-2018. <b>2021</b> , 1	0
358	Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia. <b>2021</b> , 113, 36-42	1
357	The application of harm reduction to methamphetamine use during pregnancy: a call to arms. <b>2021</b> , 3, 100418	0

- 356 Successful Implementation of an Increased Viral Risk Donor Waiting List for Preconsented Kidney Transplant Candidates in Victoria, Australia. **2021**, 7, e758
- 355 "I feel safe here": Participants identify key components of syringe access programs. **2021**, 1-15 0
- 354 Elucidating Drivers for Variations in the Explosive Human Immunodeficiency Virus Epidemic Among People Who Inject Drugs in Pakistan. **2021**, 8, ofab457
- 353 Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada. **2021**, 96, 103418 0
- 352 The effect of maladaptive schemas and psychological flexibility approaches on the addiction severity of drug addicts. **2021**, 35, 617-624 0
- 351 The distribution of hepatitis C virus infection in Shanghai, China: a time-spatial study. **2021**, 21, 974 0
- 350 What Is the Burden of Heterosexually Acquired HIV Due to HSV-2? Global and Regional Model-Based Estimates of the Proportion and Number of HIV Infections Attributable to HSV-2 Infection. **2021**, 88, 19-30 1
- 349 Young and invisible: a qualitative study of service engagement by people who inject drugs in India. **2021**, 11, e047350 0
- 348 Use of methamphetamine and alcohol among people with opioid use disorder and HIV in Vietnam: a qualitative study. **2021**, 21, 1718 2
- 347 Ongoing tobacco use in women who experience homelessness and unstable housing: A prospective study to inform tobacco cessation interventions and policies. **2022**, 125, 107125 0
- 346 Investigating a bidirectional relationship between overdose and provision of injection initiation assistance among persons who inject drugs in Vancouver, Canada and Tijuana, Mexico. **2021**, 95, 103398 0
- 345 Substance Addiction and the Hand Surgery Patient: A Comprehensive Review. **2021**, 46, 790-799
- 344 Model of Care for Microelimination of Hepatitis C Virus Infection among People Who Inject Drugs. **2021**, 10, 0
- 343 Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens. **2021**, 8, ofab474
- 342 Updates to Spectrum's case surveillance and vital registration tool for HIV estimates and projections. **2021**, 24 Suppl 5, e25777 0
- 341 The Prison and Transition Health (PATH) cohort study: Prevalence of health, social, and crime characteristics after release from prison for men reporting a history of injecting drug use in Victoria, Australia. **2021**, 227, 108970 1
- 340 Transition from injecting opioids to smoking fentanyl in San Francisco, California. **2021**, 227, 109003 8
- 339 Opium tincture-assisted treatment for opioid use disorder: A systematic review. **2021**, 129, 108519 2

338	Chronic Hepatitis B Virus in Patients with Chronic Hepatitis C Virus. <b>2021</b> , 25, 817-829	1
337	Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system. <b>2021</b> , 228, 109050	0
336	Factors associated with injury and blood-borne infection risk when providing assisted injection among people who inject drugs. <b>2021</b> , 97, 103297	
335	Opioid use disorder and Chronic Hepatitis B. <b>2021</b> , 97-123	
334	Dynamics and Correlation of Multiplex Immune Profiling Reveal Persistent Immune Inflammation In Drug Users After Withdrawal.	
333	Elbasvir and grazoprevir for the treatment of hepatitis C. <b>2021</b> , 19, 1071-1081	0
332	PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews. <b>2021</b> , 10, 39	218
331	Global HCV Burden. <b>2021</b> , 97-108	
330	A rapid review of the impacts of "Big Events " on risks, harms, and service delivery among people who use drugs: Implications for responding to COVID-19. <b>2021</b> , 92, 103127	16
329	The HIV Epidemic in the Middle East and North Africa: Key Lessons. <b>2021</b> , 3053-3079	
328	Epidemiology of Substance Use Internationally. <b>2019</b> , 19-36	3
327	Direct patient-physician communication via a hepatitis C hotline facilitates treatment initiation in patients with poor adherence. <b>2021</b> , 133, 452-460	2
326	"It's not just injecting drugs": Supervised consumption sites and the social determinants of health. <b>2020</b> , 213, 108078	8
325	Increased risk of HIV and other drug-related harms associated with injecting in public places: national bio-behavioural survey of people who inject drugs. <b>2020</b> , 77, 102663	23
324	Hepatitis C incidence and prevalence among Puerto Rican people who use drugs in New York City. <b>2020</b> , 15, 1789-1799	4
323	Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study. <b>2021</b> , 73, e69-e78	14
322	To Eliminate Hepatitis C in People Who Inject Drugs, Stop Ignoring Drug-user Health. <b>2021</b> , 73, e119-e121	1
321	Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis. <b>2021</b> , 73, e107-e118	10

320	Policing Practices and Risk of HIV Infection Among People Who Inject Drugs. <b>2020</b> , 42, 27-40	16
319	Declines in Depressive Symptoms Among People who Inject Drugs Treated With Direct-Acting Antivirals While on Opioid Agonist Therapy. <b>2020</b> , 7, ofaa380	3
318	Risk of cancer in individuals with alcohol and drug use disorders: a registry-based study in Reggio Emilia, Italy. <b>2020</b> , 29, 270-278	2
317	Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam. <b>2020</b> , 34, 2285-2294	5
316	Point-of-care hepatitis C screening with direct access referral to improve linkage of care among people with substance misuse: a pilot randomised study. <b>2020</b> ,	6
315	The Experience of Violence Against Women Who Use Injection Drugs: An Exploratory Qualitative Study. <b>2021</b> , 53, 340-352	2
314	The needle and the damage done: musculoskeletal and vascular complications associated with injected drug use. <b>2020</b> , 11, 98	4
313	Impact of funding harm reduction programs for people who inject drugs in Mexico. <b>2019</b> , 42, 157-163	2
312	The seroprevalence of untreated chronic hepatitis C virus (HCV) infection and associated risk factors in male Irish prisoners: a cross-sectional study, 2017. <b>2019</b> , 24,	7
311	The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges?. <b>2018</b> , 1, 4-13	5
310	Accelerating the elimination of hepatitis C in Kuwait: An expert opinion. <b>2020</b> , 26, 4415-4427	2
309	Distribution of Hepatitis C Virus Genotypes in Rasht, Capital City of Guilan Province, Northern Part of Iran. <b>2018</b> , 18,	1
308	An Evidence Map on Serious Games in Preventing Sexually Transmitted Infections Among Adolescents: Systematic Review About Outcome Categories Investigated in Primary Studies.. <b>2022</b> , 10, e30526	
307	Diminished Peripheral CD29hi Cytotoxic CD4+ T Cells Are Associated With Deleterious Effects During SIV Infection. <b>2021</b> , 12, 734871	
306	Could the 2010 HIV outbreak in Athens, Greece have been prevented? A mathematical modeling study. <b>2021</b> , 16, e0258267	0
305	Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis. <b>2021</b> , 18, e1003818	0
304	Management of Hepatitis B in Persons Who Inject Drugs (PWID). <b>2021</b> , 20, 158	1
303	Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. <b>2021</b> ,	3



302	Epidemiology and treatment status of hepatitis C virus infection among people who have ever injected drugs in South Korea: a prospective multicenter cohort study from 2007 to 2019 in comparison with non-PWID. <b>2021</b> , e2021077	0
301	Prevalence and factors associated with chronic venous insufficiency, leg ulceration and deep-vein thrombosis among people who inject drugs in London, UK. <b>2021</b> ,	1
300	Modelling the impact of HIV and HCV prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania. <b>2021</b> , 24, e25817	0
299	Impact of Co-occurring Drug Use, Hazardous Alcohol Use, and Mental Health Disorders on Drug Use Patterns in People With HIV and Hepatitis C Virus Infection.. <b>2021</b> , 8, ofab520	
298	Hepatitis C Treatment Among People Who Use Drugs in an Office-Based Opioid Treatment Program Versus a Syringe Exchange Program: A Real-World Prospective Clinical Trial. <b>2021</b> , 21,	
297	Addressing Hepatitis B in the Context of Hepatitis C. 1	
296	Deep Vein Thrombosis in Intravenous Drug Users: An Invisible Global Health Burden. <b>2021</b> , 13, e18457	0
295	Routes of Administration of Illicit Drugs among Young Swiss Men: Their Prevalence and Associated Socio-Demographic Characteristics and Adverse Outcomes. <b>2021</b> , 18,	2
294	Eliminating hepatitis C on the Balearic Islands, Spain: a protocol for an intervention study to test and link people who use drugs to treatment and care. <b>2021</b> , 11, e053394	
293	Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs. <b>2021</b> , 96, 103469	1
292	Outcomes of Real-World Integrated HCV Microelimination for People Who Inject Drugs: An expansion of the Punjab Model. <b>2021</b> , 41, 101148	1
291	The association between depression and oral health related quality of life in people who inject drugs. <b>2021</b> , 229, 109121	1
290	Harm Reduction Approaches for Opioid Use Disorder. <b>2019</b> , 169-180	1
289	HIV and Injection Drug Use: New Approaches to HIV Prevention. <b>2019</b> , 423-436	
288	World Hepatitis Day - July 28, 2019. <b>2019</b> , 68, 637	0
287	High Hepatitis C Prevalence in Medium-Term Residential Addiction Treatment Centers in Kurdistan Province, Iran, 2018. <b>2019</b> , 8,	
286	Treatment of chronic hepatitis C in 2019. <b>2019</b> , 21, 206-211	
285	The HIV Epidemic in the Middle East and North Africa: Key Lessons. <b>2020</b> , 1-27	1

- 284 Managing amphetamine use is critical to achieving HIV control. **2020**, 34, 1971-1973
- 283 The Opioid Epidemic and Endocarditis: Frontiers in the management of injection drug use-related endocarditis. **2021**,
- 282 Out-of-Hospital Treatment of Hepatitis C Increases Retention in Care among People Who Inject Drugs and Homeless Persons: An Observational Study. **2021**, 10, 0
- 281 Epidemiologic profile of hepatitis C virus infection and genotype distribution in Burkina Faso: a systematic review with meta-analysis. **2021**, 21, 1126
- 280 Hepatitis C Virus Screening among Medicaid-Insured Individuals with Opioid Use Disorder across Substance Use Disorder Treatment Settings. **2021**, 56, 258-263 0
- 279 Integrating public health policies in the epidemiological modeling of hepatitis C with LEHC tool: application in Austria. **2021**, 133, 461-469
- 278 Nutrition in HIV and Tuberculosis. **2021**, 243-281 1
- 277 Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study. **2020**, 11, 4
- 276 Population Size Estimation Methods: Searching for the Holy Grail. **2020**, 6, e25076 0
- 275 Violence and hepatitis C transmission in prison-A modified social ecological model. **2020**, 15, e0243106 0
- 274 Patient Centeredness in Hepatitis C Direct-Acting Antiviral Treatment Delivery to People Who Inject Drugs: A Scoping Review. **2021**, 14, 471-484
- 273 Scoping review protocol: the use of telemedicine in providing opioid agonist treatment and related psychosocial supports. **2020**, 10, e040556 0
- 272 Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania. **2021**, 99, 103458 1
- 271 National Needle and Syringe Exchange Program. **2020**, 201-223
- 270 The New Epidemiology of Human Immunodeficiency Virus Infection. **2020**, 13-24
- 269 HIV testing and ART initiation in people who inject drugs and are placed on methadone in Kachin State, Myanmar. **2020**, 10, 27-32 2
- 268 Seroepidemiology of Hepatitis C Among Drug Users at a Detoxification Center in Southeast China. **2020**, 20, 0
- 267 An Experimental Study of the Effects of Patient Race, Sexual Orientation, and Injection Drug Use on Providers' PrEP-Related Clinical Judgments. **2021**, 1 0

- 266 High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study. **2021**, 1
- 265 Complementary and Alternative Medicine for Substance Use Disorders: A Scientometric Analysis and Visualization of Its Use Between 2001 and 2020. **2021**, 12, 722240 0
- 264 Spontaneous Rectus Sheath Abscess in an Intravenous Drug User. **2020**, 12, e9009
- 263 Population Size Estimation Methods: Searching for the Holy Grail (Preprint).
- 262 Opioid Modulation of Neuronal Iron and Potential Contributions to NeuroHIV. **2021**, 2201, 139-162 1
- 261 Frequent Cannabis Use Is Negatively Associated with Frequency of Injection Drug Use Among People Who Inject Drugs in a Canadian Setting. **2021**, 6, 435-445 1
- 260 Dynamics of Epidemiological Manifestations of HIV Infection in the Gender Aspect (on the Example of the Republic of Tatarstan). **2020**, 19, 30-37
- 259 Chronic morphine administration differentially modulates viral reservoirs in SIVmac251 infected rhesus macaque model. 1
- 258 References. **2020**, 287-324
- 257 Substance Use and Co-occurring Infections (Including Immunology). **2021**, 1177-1190
- 256 No Increase in HIV Drug Resistance Mutations among Injecting Drug Users on Methadone Maintenance Therapy: A Prospective Cohort Study. **2020**, 18, 362-372
- 255 Substance use and universal access to HIV testing and treatment in sub-Saharan Africa: implications and research priorities. **2018**, 4, 26-32 12
- 254 Understanding the Reasons for Sharing Syringes or Needles to Inject Drugs: Conventional Content Analysis. **2020**, 12, 98-108
- 253 What motivates or demotivates injecting drug users to participate in hypothetical HIV vaccine efficacy trials? A qualitative study from urban Tanzania. **2020**, 4, 128-139
- 252 Patterns of Hepatitis C-Related Inpatient Mortality in the United States in the Era of Direct-Acting Antivirals. **2020**, 9, 3169-3175
- 251 Effect of hepatitis C antiviral therapy on oral lichen planus and hyposalivation in inmates.. **2022**, 35, 74-79
- 250 Gender Dynamics in Substance Use and Treatment: A Women's Focused Approach. **2022**, 106, 219-234 0
- 249 Validation of a tool to assess effectiveness of peer-recruitment for hepatitis C testing and linkage to care among people who inject drugs. **2021**, 230, 109177 1

248	A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia. <b>2021,</b>	2
247	Favorable impact in Hepatitis C related mortality following free-access to direct-acting antivirals in Spain. <b>2021,</b>	1
246	Electronic nose versus quadrupole mass spectrometry for identifying viral hepatitis C patients. <b>2021,</b>	0
245	Substance-Related and Addictive Disorders. <b>2022,</b> 235-287	
244	Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study. <b>2021,</b>	4
243	Dopamine Circuit Mechanisms of Addiction-Like Behaviors. <b>2021,</b> 15, 752420	4
242	Value of Packaged Testing for Sexually Transmitted Infections for Persons who Inject Drugs Hospitalized With Serious Injection-Related Infections.. <b>2021,</b> 8, ofab489	4
241	'In Short, We Will Deport You': Disrupted temporalities of migrants with HIV in Russia. <b>2021,</b> 1-13	
240	Drugs of Abuse and Their Impact on Viral Pathogenesis.. <b>2021,</b> 13,	0
239	Challenges of sexually transmitted infections and sexual health among people who inject drugs. <b>2021,</b> 35,	
238	HIV seroprevalence in five key populations in Europe: a systematic literature review, 2009 to 2019. <b>2021,</b> 26,	0
237	HIV prevalence among non-injecting people who use drugs and related factors in Iran: A systematic review and meta-analysis. <b>2021,</b>	
236	Meet-Test-Treat for HCV management: patients' and clinicians' preferences in hospital and drug addiction services in Italy.. <b>2022,</b> 22, 3	1
235	Association between drug use and ART use among people living with HIV who inject drugs in Vietnam, Ukraine and Indonesia: results from HPTN 074. 1-10	
234	The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study.. <b>2022,</b>	3
233	Addressing injecting related risks among people who inject both opioids and stimulants: Findings from an Australian survey of people who inject drugs.. <b>2022,</b> 15, 100398	1
232	Harm reduction via online platforms for people who use drugs in Russia: A qualitative analysis of web outreach work. <b>2020,</b>	
231	Prevalence and Characteristics of Chronic Hepatitis C Among Asian Americans Are Distinct From Other Ethnic Groups. <b>2021,</b> 55, 884-890	1

230	What motivates or demotivates intravenous drug users to participate in hypothetical HIV vaccine efficacy trial? A qualitative study from urban Tanzania. <b>2020</b> , 4, 128-139		
229	Crossroads of Drug Abuse and HIV Infection: Neurotoxicity and CNS Reservoir.. <b>2022</b> , 10,		1
228	Characteristics associated with HIV and hepatitis C seroprevalence among sexual and injecting partners of HIV positive persons who inject drugs in Nairobi and coastal Kenya.. <b>2022</b> , 22, 73		
227	Hepatitis C virus: A critical approach to who really needs treatment.. <b>2022</b> , 14, 1-44		
226	Applications of research evidence during processes to acquire approvals for syringe services program implementation in rural counties in Kentucky.. <b>2022</b> , 54, 404-412		2
225	Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population.. <b>2022</b> , 1-9		0
224	Let's End HepC: Modelling Public Health Epidemiological Policies Applied to Hepatitis C in Spain.. <b>2021</b> , 9, 735572		
223	Evidence of Potential Discriminatory HIV Pre-Exposure Prophylaxis (PrEP) Prescribing Practices for People Who Inject Drugs Among a Small Percentage of Providers in the U.S.. <b>2022</b> , 13, 21501319211063999		1
222	Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis.. <b>2021</b> ,		2
221	Socio-cognitive factors influencing access to HIV prevention services among people who inject drugs in Dar es Salaam, Tanzania: An integrated bio-behavioural survey.. <b>2022</b> , 17, e0261500		
220	Epidemiology of infective endocarditis in Africa: a systematic review and meta-analysis.. <i>The Lancet Global Health</i> , <b>2022</b> , 10, e77-e86	13.6	5
219	Ongoing HIV transmission following a large outbreak among people who inject drugs in Athens, Greece (2014-2020).. <b>2022</b> ,		0
218	Assessing the Temporality Between Transitions onto Opioid Agonist Therapy and Engagement with Antiretroviral Therapy in a Cohort of HIV-Positive People Who Use Opioids Daily.. <b>2022</b> , 1		0
217	More than saving lives: Qualitative findings of the UNODC/WHO Stop Overdose Safely (S-O-S) project.. <b>2022</b> , 100, 103482		0
216	Mortality and negative outcomes of opioid use and opioid use disorder: a six-year follow-up study.. <b>2022</b> ,		1
215	Evolutionary characteristics and immune mutation of hepatitis C virus genotype 1b among intravenous drug users in mainland, China.. <b>2022</b> ,		
214	Non-prescription pharmacy syringes sales to people who inject drugs (PWID) in Khartoum, Sudan: policy, practice, and perceptions.. <b>2022</b> , 1-6		
213	Injecting drug use opportunities and reasons for choosing not to inject: A population-based study of Australian young adults who use stimulants.. <b>2022</b> ,		

- 212 An outbreak of HIV infection among people who inject drugs in northeastern Massachusetts: findings and lessons learned from a medical record review.. **2022**, 22, 257
- 211 Personal experience and awareness of opioid overdose occurrence among peers and willingness to administer naloxone in South Africa: findings from a three-city pilot survey of homeless people who use drugs.. **2022**, 19, 17
- 210 Global Burden and Changing Trend of Hepatitis C Virus Infection in HIV-Positive and HIV-Negative MSM: A Systematic Review and Meta-Analysis.. **2021**, 8, 774793 ○
- 209 Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 - is the precautionary principle applicable?. **2021**, 26, ○
- 208 Fatalities in Patients with an Opioid Use Disorders. **2022**, 1-17
- 207 Endogenous Endophthalmitis-The Clinical Significance of the Primary Source of Infection.. **2022**, 11, ○
- 206 UK guideline for the use of HIV post-exposure prophylaxis 2021.. **2022**, ○
- 205 HIV Prevalence and Related Behaviors Among People Who Inject Drugs in Iran from 2010 to 2020.. **2022**, 1 1
- 204 Simulated Cost-effectiveness and Long-term Clinical Outcomes of Addiction Care and Antibiotic Therapy Strategies for Patients With Injection Drug Use-Associated Infective Endocarditis.. **2022**, 5, e220541 2
- 203 The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience.. **2022**, 14, ○
- 202 A global systematic review of hepatitis C elimination efforts through micro-elimination.. **2022**, 1
- 201 The effectiveness of low dead space syringes for reducing the risk of hepatitis C virus acquisition among people who inject drugs - findings from a national survey in England, Wales, and Northern Ireland.. **2022**,
- 200 Barriers of linkage to HCV viremia testing among people who inject drugs in Georgia.. **2022**, 17, 23
- 199 Prevalence and Incidence of Hepatitis C Infection Amongst Men Who Have Sex with Men in a Population-Based PrEP Program in British Columbia, Canada.. **2022**,
- 198 Short Take: Collecting Data from a Vulnerable Population during the COVID-19 Pandemic. 1525822X2210773 ○
- 197 Characterization of basal ganglia volume changes in the context of HIV and polysubstance use.. **2022**, 12, 4357 ○
- 196 Key Role of Multidisciplinary Collaboration towards Global Elimination of HCV Infection.. **2022**, 19,
- 195 Accessible Hepatitis C Care for People Who Inject Drugs: A Randomized Clinical Trial.. **2022**, 2

194	High-Risk Injection-Related Practices Associated with anti-HCV Positivity among Young Adults Seeking Services in Three Small Cities in Wisconsin.. <b>2022</b> , 1-9	
193	Understanding social and environmental factors and their contribution mechanisms to HIV transmission among heterosexual men in Indonesia.	
192	Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials.. <b>2022</b> , 17, e0266142	1
191	Vulnerability Conditions in a Cohort of Men Who Have Sex with Men Who Engage in Chemsex in Barcelona City: a Cross-Sectional Study. 1	0
190	Contingency Management and SARS-CoV-2 Testing Among People Who Inject Drugs.. <b>2022</b> , 3335492210743850	
189	Total Joint Arthroplasty in Homeless Patients at an Urban Safety Net Hospital.. <b>2022</b> ,	
188	Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users.. <b>2022</b> , 58,	0
187	Exploring why patients in heroin-assisted treatment are getting incarcerated-a qualitative study.. <b>2022</b> , 22, 169	
186	Hepatitis C Treatment Outcomes Among People Who Inject Drugs Accessing Harm Reduction Settings in Kenya.. <b>2022</b> ,	0
185	Liver Disease Screening and Hepatitis C Virus Elimination in Taiwan Rural Indigenous Townships: Village-By-Village Screening and Linking to Outreach Hepatology Care.. <b>2022</b> , 19,	2
184	Correlates of 90-Day Mortality Among People Who Do and Do Not Inject Drugs With Infective Endocarditis in Seattle, Washington.. <b>2022</b> , 9, ofac150	
183	Targeting natural products against SARS-CoV-2.. <b>2022</b> , 1	2
182	Peer support in small towns: A decentralized mobile HCV clinic for people who inject drugs.. <b>2022</b> ,	1
181	Hepatitis C antibody prevalence, correlates and barriers to care among people who inject drugs in Central California.. <b>2022</b> ,	0
180	Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study.. <b>2022</b> ,	0
179	Hepatitis C cure as a 'gathering': Attending to the social and material relations of hepatitis C treatment.. <b>2022</b> ,	2
178	Adapted Break The Cycle for Avant Garde Intervention to Reduce Injection Assisting and Promoting Behaviours in People Who Inject Drugs in Tallinn, Estonia: A Pre- Post Trial.	0
177	Modeling the impact of interventions during an outbreak of HIV infection among people who inject drugs in 2012-2013 in Athens, Greece.. <b>2022</b> , 234, 109396	0

- 176 A gender lens is needed in hepatitis C elimination research.. **2022**, 103, 103654 1
- 175 Dynamics and correlations in multiplex immune profiling reveal persistent immune inflammation in male drug users after withdrawal.. **2022**, 107, 108696 1
- 174 Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma.. **2021**, 108684 0
- 173 Evaluating the impact and cost-effectiveness of scaling-up HCV treatment among people who inject drugs in Ukraine. 1
- 172 A syndemic examination of injecting drug use, incarceration and multiple drug-related harms in French opioid users.. **2021**, ahead-of-print,
- 171 Injection drug use practices and HIV infection among people who inject drugs in Kigali, Rwanda: a cross-sectional study.. **2021**, 18, 130
- 170 Barriers and facilitators of HIV and hepatitis C care among people who inject drugs in Nairobi, Kenya: a qualitative study with peer educators.. **2021**, 18, 133 0
- 169 Addiction Treatment as Prison Governance: A Critical Discourse Analysis of Methadone Delivery in Kyrgyz Prisons. **2022**, 49, 106-120 1
- 168 Prevalence of hepatitis B and C among female sex workers in Togo, West Africa. **2021**, 16, e0259891 1
- 167 Hepatitis C Vaccination: Where We Are and Where We Need to Be.. **2021**, 10, 1
- 166 Variation in US drug overdose mortality within and between Hispanic/Latine subgroups: A disaggregation of national data. **2022**, 100095 0
- 165 Table\_1.DOCX. **2019**,
- 164 DataSheet\_1.docx. **2020**,
- 163 Table\_1.docx. **2020**,
- 162 Population Size Estimation of Drug Users in Isfahan City (Iran) Using Network Scale-up Method in 2018.. **2021**, 13, 249-258 1
- 161 Editorial on 'Epidemiology of HIV infection and associated behaviours among people who inject drugs in England, Wales, and Northern Ireland: nearly 40'years on'.. **2022**,
- 160 Treating people where they are: Nurse-led micro-elimination of hepatitis C in supported housing sites for networks of people who inject drugs in Victoria, Canada.. **2022**, 0
- 159 Multidisciplinary and Integrated Treatment for Substance Use Disorders and Hepatitis C in an Addiction Treatment Service in India. 025371762210860



- 158 Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: An international randomised controlled trial.. **2022**, 0
- 157 Internet use and uptake of a web-based prevention and risk reduction intervention for persons who use drugs in New York City - WebHealth4Us study (2013-2016).. **2022**, 43, 1119-1126
- 156 Hepatitis C antibody testing among opioid agonist therapy recipients, Victoria, Australia, 2012 to 2020.. **2022**, 104, 103696
- 155 Seroprevalence of Hepatitis B, C and D in Vietnam: A systematic review and meta-analysis.. **2022**, 24, 100468 0
- 154 Impact of COVID-19 on substance use disorder treatment services in Kenya: Qualitative findings from healthcare providers.. **2022**, 105, 103710
- 153 Diagnosis and Management of Infective Endocarditis in People Who Inject Drugs: JACC State-of-the-Art Review.. **2022**, 79, 2037-2057 3
- 152 Hepatitis C Virus Prevalence, Medical Status Awareness and Treatment Engagement among Homeless People Who use Drugs: Results of a Street Outreach Study. **2022**, 16, 117822182210958 1
- 151 Pre-Exposure Prophylaxis Barriers, Facilitators and Unmet Need Among Rural People Who Inject Drugs: A Qualitative Examination of Syringe Service Program Client Perspectives. **2022**, 13, 0
- 150 Can Telemedicine Optimize the HCV Care Cascade in People Who Use Drugs? Features of an Innovative Decentralization Model and Comparison with Other Micro-Elimination Strategies. **2022**, 11, 805 0
- 149 How to be self-reliant in the context of stigma? The dilemma of people who inject drugs in Vietnam. 1-16
- 148 Substance-Related and Addictive Disorders. **2022**,
- 147 Epidemiology of hepatitis B virus and/or hepatitis C virus infections among people living with human immunodeficiency virus in Africa: A systematic review and meta-analysis. **2022**, 17, e0269250 0
- 146 Hepatitis C Virus Epidemiology in Lithuania: Situation before Introduction of the National Screening Programme. **2022**, 14, 1192 0
- 145 The prevalence of substance abuse and associated factors among male prisoners in Karachi jails, Pakistan. **2022**,
- 144 Breakthroughs in hepatitis C research: from discovery to cure. 5
- 143 High efficacy of Glecaprevir/Pibrentasvir for HCV-Infected individuals with active drug use. **2022**, 0
- 142 Interventions to Improve Uptake of Direct-Acting Antivirals for Hepatitis C Virus in Priority Populations: A Systematic Review. 10,
- 141 Injection and Sexual Behavior Profiles among People Who Inject Drugs in Miami, Florida. 1-9

- 140 Sustained Virologic Response Rates Before and After Removal of Sobriety Restriction for Hepatitis C Virus Treatment Access. 003335492210993 0
- 139 Dealing with the epidemic of endocarditis in people who inject drugs. **2022**, 0
- 138 Plasma Virome Reveals Blooms and Transmission of Anellovirus in Intravenous Drug Users with HIV-1, HCV, and/or HBV Infections. 0
- 137 Correlation of Trends in the Incidence of Selected Infectious Diseases with Healthcare Expenditures: An Ecological Study. **2022**, 7, 365-372
- 136 Housing instability and violence among women who use drugs in Dar es Salaam, Tanzania. **2022**, 19,
- 135 Viral hepatitis: A narrative review of hepatitis A-E. **2022**, 10, 99-121
- 134 Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R). **2022**, 14, 1541
- 133 A systematic review and meta-analysis of the evidence for community-based HIV testing on men's engagement in the HIV care cascade. 095646242211112 0
- 132 Homelessness and health-related outcomes: an umbrella review of observational studies and randomized controlled trials. **2022**, 20, 0
- 131 Status of the HIV epidemic in key populations in the Middle East and north Africa: knowns and unknowns. **2022**, 9, e506-e516 3
- 130 Determinants of health among people who use illicit drugs in the conflict-affected countries of Afghanistan, Colombia and Myanmar: a systematic review of epidemiological evidence. **2022**, 16,
- 129 Elbasvir/grazoprevir for the treatment of hepatitis C virus infection in people with opioid use disorder. 1-3
- 128 Prevalence of Chronic Infection by Hepatitis C Virus in Asymptomatic Population With Risk Factors in Cartagena, Colombia. 9,
- 127 Systematic Review of Hepatitis C Virus Prevalence in the WHO Western Pacific Region. **2022**, 14, 1548
- 126 Prevalence of mental disorders among people with opioid use disorder: A systematic review and meta-analysis. **2022**, 238, 109551 2
- 125 HCV genotype 4 subtypes in people who inject drugs in sub-Saharan Africa. **2022**, 7, 699 0
- 124 Policy actor views on structural vulnerability in harm reduction and policymaking for illegal drugs: A qualitative study. **2022**, 108, 103805
- 123 Impact of safe consumption facilities on individual and community outcomes: A scoping review of the past decade of research. **2022**, 2, 100046

- 122 Key population size, HIV prevalence, and ART coverage in sub-Saharan Africa: systematic collation and synthesis of survey data. 0
- 121 Collaborative Referral Model to Achieve Hepatitis C Micro-Elimination in Methadone Maintenance Treatment Patients during the COVID-19 Pandemic. **2022**, 14, 1637 1
- 120 Care Navigation Increases Initiation of Hepatitis C Treatment After Release From Prison in a Prospective Randomized Controlled Trial: The C-LINK Study. **2022**, 9, 2
- 119 Factors Associated with HIV Risk and Vulnerability Among Injecting Drug Users in Afghanistan: A Narrative Review. Volume 14, 331-339
- 118 Assessment of Tennessee county-level vulnerability to hepatitis C virus and HIV outbreaks using socioeconomic, healthcare, and substance use indicators. **2022**, 17, e0270891
- 117 Prevalence and associates of non-fatal overdose among people who inject drugs in Saveh, Iran. **2022**, 17, 0
- 116 Reliving it All Over Again: Uncanny Temporalities of Injection Drug Use and Hepatitis C Diagnosis in Southwest Virginia, USA. 1-14
- 115 Challenges and best practices for hepatitis C care among people who inject drugs in resource limited settings: focus group discussions with healthcare providers in Kenya. 1-11
- 114 Acute injection-related infections requiring hospitalisation among people who inject drugs: Clinical features, microbiology and management. 0
- 113 The Role of Context in Integrating Buprenorphine into a Drop-In Center in Kampala, Uganda, Using the Consolidated Framework for Implementation Research. **2022**, 19, 10382
- 112 Changes in Alcohol Use during Hepatitis C Treatment in Persons Who Inject Drugs.
- 111 Implementation of a Dyad-Based Intervention to Improve Antiretroviral Therapy Adherence Among HIV-Positive People Who Inject Drugs in Kazakhstan: A Randomized Trial. 104973152211175
- 110 High Satisfaction with Patient-Centered Telemedicine for Hepatitis C Virus Delivered to Substance Users: A Mixed-Methods Study.
- 109 Estimating the number of people who inject drugs using repeated respondent-driven sampling (RDS) in a community-based program: implications for the burden of hepatitis C and HIV infections and harm reduction coverage.
- 108 Public injecting and its association with mental health and other drug-related outcomes among people who inject drugs in Iran. **2022**, 108868
- 107 Hepatitis C antibody prevalence and behavioral correlates in people who inject drugs attending harm reduction services in Lisbon, Portugal. 10,
- 106 Country versus pharmaceutical company interests for hepatitis C treatment.
- 105 Direct-acting antiviral therapy for chronic hepatitis C among incarcerated people who inject drugs.

104	Exhausted practical sovereignty and lateral agency: Non-uptake of treatment for hepatitis C in the antiviral era. <b>2022</b> , 107, 103771	1
103	HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates. <b>2022</b> , 100580	1
102	Understanding injecting drug use in Afghanistan: A scoping review. <b>2022</b> , 17,	1
101	Point-of-care hepatitis C reflex testing and treatment referral in methadone clinic settings in Hong Kong pilot study. <b>2022</b> , 5, 8-12	0
100	Epigenetics of Drug Addiction. <b>2023</b> , 625-637	0
99	Hepatitis C Genotype Distribution Changing Through Years in the Kahramanmaraş Region. <b>2022</b> , 28, 67-71	0
98	Acceptability and feasibility of long-acting injectable antiretroviral therapy for HIV-infected persons who inject drugs in Vietnam: A qualitative study. <b>2022</b> , 100603	0
97	Usability and acceptability of oral fluid hepatitis C self-testing among people who inject drugs in Coastal Kenya: a cross-sectional pilot study. <b>2022</b> , 22,	1
96	Modelling the impact of HIV and HCV prevention and treatment interventions among people who inject drugs in Kenya. Publish Ahead of Print,	0
95	Post-crisis imaginaries in the time of direct-acting antiviral hepatitis C treatment. 0961463X2211287	0
94	Injecting Alone: Practices and Preferences among People Who Inject Drugs in New York City. 1-9	0
93	Medical injection and infusion practices among HIV-seronegative people and people living with HIV: a behavioural survey of 10 HIV testing and opportunistic infections/antiretroviral therapy sites in Cambodia. <b>2022</b> , 12, e065026	0
92	Rates, characteristics and toxicology of cocaine-related deaths in Australia, 2000-2021.	0
91	The association of gender with receptive and distributive needle sharing among individuals who inject drugs. <b>2022</b> , 19,	2
90	It was horrible for that community, but not for the way we had imagined it A qualitative study of family physicians' experiences of caring for communities experiencing marginalisation during COVID-19. <b>2022</b> , 100176	0
89	Infective endocarditis in developing countries: An update. 9,	0
88	Measuring and Addressing Stigma Within HIV Interventions for People Who Use Drugs: a Scoping Review of Recent Research. <b>2022</b> , 19, 301-311	0
87	Advancing virtual primary care for people with opioid use disorder (VPC OUD): a mixed-methods study protocol. <b>2022</b> , 12, e067608	0

86	Securing Wider EU Commitment to the Elimination of HCV.	0
85	Pathways into Opioid Dependence: Evidence from Practice Variation in Emergency Departments. <b>2022</b> , 14, 271-300	1
84	Long-Term Follow-Up of Thalassemia Major Patients with Hepatitis C Virus Treated with Sofosbuvir and Daclatasvir: A Cohort Study. <b>2022</b> ,	0
83	Interventions to prevent HIV and Hepatitis C among people who inject drugs: Latest evidence of effectiveness from a systematic review (2011 to 2020). <b>2022</b> , 109, 103872	0
82	Fatalities in Patients with Opioid Use Disorders. <b>2022</b> , 1851-1867	0
81	Profiles and health risks (STIs, HCV, HIV) of injecting drug users. <b>2022</b> ,	0
80	The role of depression in secondary HIV transmission among people who inject drugs in Vietnam: A mathematical modeling analysis. <b>2022</b> , 17, e0275995	0
79	Key Population Size Estimation to Guide HIV Epidemic Responses in Nigeria: Bayesian Analysis of 3-Source Capture-Recapture Data. <b>2022</b> , 8, e34555	0
78	Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: a modelling study.	0
77	The signal-to-cutoff ratios to predict HCV infection among people who inject drugs.	0
76	Neurocognitive Functions in Patients with Comorbid Hepatitis C and Opioid Dependence: A Comparative Study. 025371762211274	0
75	Collaborative learning and response to opioid misuse and HIV prevention in Ukraine during war. <b>2022</b> , 9, 852-854	1
74	Prevalence and Factors Associated with Neck Injection among People who Inject Drugs in San Francisco, California. <b>2022</b> , 109686	0
73	Modelling the contribution of incarceration and public health oriented drug law reform to HCV transmission and elimination among PWID in Tijuana, Mexico. <b>2022</b> , 110, 103878	0
72	It's a different way to do medicine—Exploring the affordances of telehealth for hepatitis C healthcare. <b>2022</b> , 110, 103875	0
71	Hepatitis C cure and medications for opioid use disorder improve health-related quality of life in patients with opioid use disorder actively engaged in substance use. <b>2023</b> , 111, 103906	0
70	Association of Intravenous Drug Use and Length of Stay Following Infective Endocarditis. <b>2023</b> , 282, 239-245	0
69	Impact of COVID-19 & Response Measures on HIV-HCV Prevention Services and Social Determinants in People Who Inject Drugs in 13 Sites with Recent HIV Outbreaks in Europe, North America and Israel.	0

- 68 Injection Drug Use-Associated Infective Endocarditis. ○
- 67 Combined COVID-19 vaccination and hepatitis C virus screening intervention in marginalised populations in Spain. ○
- 66 HIV risk perception and risk taking among people who inject drugs in Saveh, in Central Iran: findings from a national study. 1-6 ○
- 65 Social work with people who use drugs during the Covid-19 pandemic - A mixed methods study. 1-14 ○
- 64 Hepatitis C virus screening reactive among blood donors in mainland China: A systematic review and meta-analysis. 1
- 63 Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial. **2022**, 7, 1112-1127 ○
- 62 Attitudes toward harm reduction and low-threshold healthcare during the COVID-19 pandemic: qualitative interviews with people who use drugs in rural southern Illinois. **2022**, 19, ○
- 61 Association of Illicit Fentanyl Use with Injection Risk Practices Among People who Inject Drugs. ○
- 60 A scoping review of qualitative research on barriers and facilitators to the use of supervised consumption services. **2023**, 111, 103910 ○
- 59 Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis. **2023**, 111, 103917 ○
- 58 Salles de consommation à moindre risque : opinion et volonté d'utilisation des personnes injectrices de substances psychoactives à Marseille, France. **2023**, 71, 101421 ○
- 57 Experiences of Hope after Treatment of Hepatitis C Infection—A Qualitative Study. **2022**, 19, 15732 ○
- 56 Gender Differences in HIV, HCV risk and Prevention Needs Among People who Inject drug in Vietnam. ○
- 55 Incorporating social determinants of health into the mathematical modeling of HIV/AIDS. **2022**, 12, ○
- 54 Development and Validation of a Risk Prediction Tool to Identify People at Greater Risk of Having Hepatitis C among Drug Users. **2022**, 19, 15677 ○
- 53 Inconsistent Condom Use and Risk Taking Among People Who Inject Drugs in Saveh: Finding from a Cross-Sectional Study in Iran. ○
- 52 Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation. **2022**, 19, ○
- 51 Preserving Dignity Through Expanded and Sustained Access to Buprenorphine. **2022**, ○

50	Dopamine, Immunity and Disease. PHARMREV-AR-2022-000618	1
49	Provision of drug and alcohol services amidst COVID-19 pandemic: a qualitative evaluation on the experiences of service providers.	o
48	Does sexuality matter? A cross-sectional study of drug use, social injecting, and access to injection-specific care among men who inject drugs in Melbourne, Australia.	o
47	Patient reported outcomes during and following HCV direct-acting antiviral treatment among people who inject drugs. <b>2023</b> ,	o
46	Associations between the prevalence of chronic hepatitis B among people who inject drugs and country-level characteristics: An ecological analysis.	o
45	Substance use disorder treatment and technology access among people who use drugs in rural areas of the United States: A cross-sectional survey.	o
44	Pilot Outreach Program in Remedising the Promising Step toward HCV Elimination among People Who Inject Drugs. <b>2023</b> , 20, 501	o
43	Geographical disparities of people who inject drugs and associated needle sharing in the selected states in Nigeria: A call for urgent intervention programmes. <b>2022</b> , 22, 11	o
42	Complications infectieuses de la pratique du Chemsex. <b>2022</b> , 1, 166-171	o
41	Estimating prevalence and modelling correlates of HIV test positivity among Female Sex Workers, Men who have Sex with Men, People who Inject Drugs, Transgender People and Prison Inmates in Sierra Leone, 2021.	o
40	Associations of socioeconomic status with infectious diseases mediated by lifestyle, environmental pollution and chronic comorbidities: a comprehensive evaluation based on UK Biobank. <b>2023</b> , 12,	o
39	Does sexuality matter? A cross-sectional study of drug use, social injecting, and access to injection-specific care among men who inject drugs in Melbourne, Australia. <b>2023</b> , 20,	o
38	Medical Complications of Injection Drug Use [Part II. <b>2023</b> , 2,	o
37	A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa. <b>2023</b> , 20,	o
36	The effect of different types of migration on symptoms of anxiety or depression and experience of violence among people who use or inject drugs in Kachin State, Myanmar. <b>2023</b> , 20,	o
35	The Impact of Needle and Syringe Exchange Programs on HIV-Related Risk Behaviors in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis Examining Individual- Versus Community-Level Effects.	o
34	Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review. <b>2023</b> , 11, e659-e672 <sup>o</sup>	o
33	Patient-provider relationships: Opioid use disorder and HIV treatment in Vietnam. <b>2023</b> , 7, 100151	o

- 32 Injecting Practices During and After Hepatitis C Treatment and Associations with Not Achieving Cure Among Persons Who Inject Drugs. **2023**, 109878 ○
- 31 Drug use, drug use disorders, and treatment services in the Eastern Mediterranean region: a systematic review. **2023**, 10, 282-295 ○
- 30 Data Analysis Architecture using Techniques of Machine Learning for the Prediction of the Quality of Blood Fonations against the Hepatitis C Virus. **2022**, ○
- 29 Changes in HIV incidence in people who inject drugs in Ireland from 2000 to 2018: longitudinal observational study. ○
- 28 HIV treatment, antiretroviral adherence and AIDS mortality in people who inject drugs: a scoping review. ○
- 27 Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs. **2023**, 24, ○
- 26 Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya. **2023**, 113, 103959 ○
- 25 Need for integration of hepatitis C (HCV) services in community-based settings for people who inject drugs: results from a global values and preferences survey. **2023**, 20, ○
- 24 The forgotten people: Hepatitis B virus (HBV) infection as a priority for the inclusion health agenda. 12, 1 ○
- 23 Methods for Assessing Spillover in Network-Based Studies of HIV/AIDS Prevention among People Who Use Drugs. **2023**, 12, 326 ○
- 22 Development and implementation of site-specific Hepatitis C Virus treatment workflows for treating vulnerable, high-risk populations: protocol of the Erase Hep C study, a prospective single-arm intervention trial. ○
- 21 The infection rates of HBV and HCV decreased significantly in Zhejiang Province, China: A comparative study based on the data of two sero-epidemiological surveys in 1992 and 2020. ○
- 20 Daily opioid and stimulant co-use and nonfatal overdoses in the context of social disadvantage: Findings on marginalized populations. **2023**, 208986 ○
- 19 Factors associated with receptive injection equipment sharing among people who inject drugs: findings from a multistate study at the start of the COVID-19 pandemic. **2023**, 20, ○
- 18 THE RELATIONSHIP BETWEEN THE TIME OF USE OF ANTIRETROVIRAL THERAPY (ART) AND THE AMOUNT OF VIRAL LOAD IN ACQUIRED IMMUNODEFICIENCY SYNDROME. 24-28 ○
- 17 Service Utilization among Persons Who Inject Drugs Attending a Syringe Exchange Program in New York State. **2023**, 58, 649-656 ○
- 16 Trends in HIV incidence following scale-up of harm reduction interventions among people who inject drugs in Kachin, Myanmar, 2008-2020: analysis of a retrospective cohort dataset. **2023**, 100718 ○
- 15 HCV Genotype Distribution Among People Who Inject Drug in Turkey: Findings from Multicenter and Cross-Sectional Study. **2023**, 17, 117822182311573 ○



- 14 The burden of hepatitis C virus in the world, China, India, and the United States from 1990 to 2019. 11, ○
- 13 Recidivism of Individuals Who Completed Schedule I Drugs Deferred Prosecution Treatment: A Population-Based Follow-Up Study from 2008 to 2020 in Taiwan. ○
- 12 Injection Drug Use and Sexual Risk Behaviors Among People who Inject Drugs in Ukraine: A Random-Intercept Latent Transition Analysis. ○
- 11 HIV and Addiction Services for People Who Inject Drugs: Healthcare Provider Perceptions on Integrated Care in the U.S. South. **2023**, 14, 215013192311612 ○
- 10 Provider Implicit Bias in Prescribing HIV Pre-exposure Prophylaxis (PrEP) to People Who Inject Drugs. ○
- 9 Characterization of Hepatitis C virus circulating among injecting drug users (IDU) in Kilifi county, Kenya. **2020**, 8, 23-30 ○
- 8 Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review. **2023**, 11, e673-e683 ○
- 7 Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis. **2023**, ○
- 6 Predictors of Significant Liver Fibrosis in People with Chronic Hepatitis C Who Inject Drugs in the Czech Republic. **2023**, 13, 932 ○
- 5 Tuberculosis Among People Who Use Drugs: Multilevel Considerations for Prevention, Diagnosis, and Treatment. **2023**, 669-696 ○
- 4 Mixed-methods evaluation of point-of-care hepatitis C virus RNA testing in a Scottish prison. **2023**, 13, e068604 ○
- 3 Estimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics. **2023**, 6, e237888 ○
- 2 New data confirm lack of progress in harm reduction after three decades of proven evidence of effectiveness. ○
- 1 The Synthetic Opioid Fentanyl Increases HIV Replication and Chemokine Co-Receptor Expression in Lymphocyte Cell Lines. **2023**, 15, 1027 ○